1
|
Tagawa ST, Thomas C, Sartor AO, Sun M, Stangl-Kremser J, Bissassar M, Vallabhajosula S, Castellanos SH, Nauseef JT, Sternberg CN, Molina A, Ballman K, Nanus DM, Osborne JR, Bander NH. Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591. J Clin Oncol 2024; 42:842-851. [PMID: 37922438 PMCID: PMC10906595 DOI: 10.1200/jco.23.00573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Revised: 08/03/2023] [Accepted: 09/06/2023] [Indexed: 11/05/2023] Open
Abstract
PURPOSE Novel therapies are needed to extend survival in metastatic castration-resistant prostate cancer (mCRPC). Prostate-specific membrane antigen (PSMA), a cell surface antigen overexpressed in PC, provides a validated target. This dose-escalation study investigated the safety, efficacy, maximum tolerated dose (MTD), and recommended phase II dose (RP2D) for 225Ac-J591, anti-PSMA monoclonal antibody J591 radiolabeled with the alpha emitter actinium-225. METHODS Following investigational new drug-enabling preclinical studies, we enrolled patients with progressive mCRPC that was refractory to or who refused standard treatment options (including androgen receptor pathway inhibitor and had received or been deemed ineligible for taxane chemotherapy). No selection for PSMA was performed. Patients received a single dose of 225Ac-J591 at one of seven dose-escalation levels followed by expansion at the highest dose. Primary end point of dose-escalation cohort was determination of dose-limiting toxicity (DLT) and RP2D. RESULTS Radiochemistry and animal studies were favorable. Thirty-two patients received 225Ac-J591 in an accelerated dose-escalation design (22 in dose escalation, 10 in expansion). One patient (1 of 22; 4.5%) experienced DLT in cohort 6 (80 KBq/kg) but none in cohort 7; MTD was not reached, and RP2D was the highest dose level (93.3 KBq/kg). The majority of high-grade adverse events (AEs) were hematologic with an apparent relationship with administered radioactivity. Nonhematologic AEs were generally of low grade. Prostate-specific antigen (PSA) declines and circulating tumor cell (CTC) control were observed: 46.9% had at least 50% PSA decline at any time (34.4% confirmed PSA response), and protocol-defined CTC count response occurred in 13 of 22 (59.1%). CONCLUSION To our knowledge, this is the first-in-human phase I dose-escalation trial of a single dose of 225Ac-J591 in 32 patients with pretreated progressive mCRPC demonstrated safety and preliminary efficacy signals. Further investigation is underway.
Collapse
Affiliation(s)
- Scott T. Tagawa
- Division of Hematology & Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY
- Department of Urology, Weill Cornell Medicine, New York, NY
- Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital, New York, NY
| | - Charlene Thomas
- Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY
| | - A. Oliver Sartor
- Departments of Medicine and Urology, Tulane University School of Medicine, New Orleans, LA
| | - Michael Sun
- Division of Hematology & Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY
| | | | - Mahelia Bissassar
- Division of Hematology & Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY
| | | | - Sandra Huicochea Castellanos
- Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital, New York, NY
- Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, NY
| | - Jones T. Nauseef
- Division of Hematology & Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY
- Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital, New York, NY
| | - Cora N. Sternberg
- Division of Hematology & Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY
- Department of Urology, Weill Cornell Medicine, New York, NY
- Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital, New York, NY
| | - Ana Molina
- Division of Hematology & Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY
- Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital, New York, NY
| | - Karla Ballman
- Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital, New York, NY
- Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine, New York, NY
| | - David M. Nanus
- Division of Hematology & Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY
- Department of Urology, Weill Cornell Medicine, New York, NY
- Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital, New York, NY
| | - Joseph R. Osborne
- Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital, New York, NY
- Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, NY
| | - Neil H. Bander
- Department of Urology, Weill Cornell Medicine, New York, NY
- Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital, New York, NY
| |
Collapse
|
2
|
Nauseef JT, Thomas C, Ho B, Martinez Zuloaga J, Gonzalez BD, Sun M, Sartor AO, Singh S, Bissassar M, Fernandez E, Tan A, Patel A, Naiz MO, Vallabhajosula S, Molina AM, Sternberg CN, Nanus DM, Osborne J, Bander NH, Tagawa ST. Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.6_suppl.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
77 Background: Prostate Specific Membrane Antigen (PSMA) is a conserved cell surface protein in PC and is used for targeted imaging and therapeutics. Antibodies circulate longer than small molecules and are less likely to reach luminal PSMA on normal organs. Here we report PROs and longer-term AEs from the dose-escalation and expansion cohorts of a first-in-human study of combined monoclonal antibody and potent alpha emitter (225Ac-J591). Methods: Eligible subjects with mCPRC were administered 225Ac-J591. Initial to maximum doses were 13.3 to 93.3 KBq/kg). AEs are reporting using CTCAE v5 and PROs, including pain (BPI-SF) and quality of life (QOL, FACT-P), and associations with PSA response were also examined. Results: A total of 32 subjects (one enrolled in both dose-escalation and expansion) were treated with a single dose of 225Ac-J591 across 7 dose levels with expansion at the level (93.3 KBq/kg, n = 16). Median age 69.5 (52-89) and PSA 149.1 (4.8-7168.4). All subjects had at least 1 AE of any grade. Most common were fatigue (31/32, 1 Gr > 2), anorexia (25/32, all Gr 1-2), and thrombocytopenia (25/32, 3 Gr 3, 2 Gr 4). Xerostomia was observed in 14/32 subjects (all Gr 1), 7 of whom had prior 177Lu-PSMA. Pain flare was reported in 43% (17/32) subjects (11 Gr 1, 6 Gr 2). 19 had evaluable PROs at baseline and efficacy visit (week 12). Pain severity (p = 0.8) and interference from pain (p = 0.4) were unchanged from baseline to 12 weeks, yet better PSA response (by percent) was associated with reduced pain severity (r = 0.7, p = 0.0023). Despite at least one AE in each subject, total FACT-P was not significantly changed after treatment (p = 0.2), but emotional well-being declined over time (15 [10.0, 18.0] v 10.0 [7.5, 13.0], p = 0.011). Reduction in median emotional well-being reached clinically important score differences. When stratified by AE, subjects with xerostomia had lower FACT-P total scores, but no difference was observed between those with and without pain. PSA response was not associated with change in QOL or subscales. Conclusions: Pain and quality of life in subjects with mCRPC did not change, on average, from baseline to 12 weeks after treatment with 225Ac-J591. This is despite preliminary evidence of clinical efficacy being accompanied by frequent, treatment emergent AEs. A promising trend toward improved pain in those with PSA response warrants further analysis. Small numbers limited statistical power for testing other subgroup associations. Additional correlations with pretreatment sites of disease, performance status, and adverse event distribution are ongoing. Assessment of changes in PROs in the follow up studies [NCT04506567] are underway. Clinical trial information: NCT03276572.
Collapse
Affiliation(s)
- Jones T. Nauseef
- New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Cora N. Sternberg
- Englander Institute for Precision Medicine, Weill Cornell Medicine, Hematology/Oncology, New York, NY
| | | | | | | | | |
Collapse
|
3
|
Nauseef JT, Thomas C, Sun M, Sartor AO, Singh S, Bissassar M, Fernandez E, Tan A, Patel A, Martinez Zuloaga J, Naiz MO, Imad D, Vallabhajosula S, Molina AM, Sternberg CN, Nanus DM, Osborne J, Bander NH, Perk T, Tagawa ST. Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.6_suppl.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
37 Background: We have previously reported a dose-intense single-cycle of 177Lu-PSMA-617 was effective in pretreated patients with mCRPC without requiring PSMA-positive imaging for enrollment. Prior post-hoc analyses of these data using approximate quantification of exclusively the most PSMA-positive disease sites have demonstrated associations between PSA response and PFS with pre-treatment 68Ga-PSMA11-PET signal. Greater sophistication in pre- and post-treatment evaluation of PSMA-expression in tumor and normal organs may allow for better patient selection and prediction of toxicities. Methods: A total of 50 patients were treated on a phase I/II study of fractionated-dose (D1, 15) 177Lu-617-PSMA. Quantification using artificial intelligence (AI) were used to measure pre- and post-treatment PSMA signal intensity. Scoring cutoffs with confidence intervals around scan variation were empirically established from a subset of test/re-test of subjects within 24h without intervening therapy. A variety of measurements were performed including SUVmean across all detectable tumor lesions, volume of lesions, and SUVtotal (Total + Volume), as well as select normal organs and changes after treatment. Associations with survival were tested via Cox proportional hazard models in univariate analyses and associations with adverse events (AEs) and PSA responses were via assessed via Wilcoxon rank sum tests. Results: 13 subjects were selected to complete AI-based quantification and associated survival analyses. Among these, 10 (77%) experienced any PSA decline, with 8 (62%) with PSA50 and 3 (23%)with PSA90. Median overall survival (OS) was 17.0 mos (10, NA) via Kaplan-Meier estimates. In univariate analysis, pretreatment SUVmean was associated with improved PFS (HR 0.66, 95% CI 0.49-0.90, p = 0.009) and OS (HR 0.81, 95% CI 0.65-1.00, p = 0.048). The metrics most strongly associated with PSA50 were pretreatment SUVmean (median [IQR]: 7.66 [6.52, 10.54] v 3.50 [3.02, 3.56], p = 0.019) and SUV Total (14982 [11110, 20595] v 1303 [576, 1512], p = 0.019), and change in Volume (-27 [-44, -20] v 145 [38, 154], p = 0.006) and SUVtotal (-57 [-67, -35] v 132 [9, 269], p = 0.030). Subjects with xerostomia had higher salivary gland SUVmax (pretreatment and change in after treatment). Those with pain flare had lower pretreatment SUV scores (Mean, Max, Total) in unaffected portions of bony skeleton. Conclusions: Sophisticated AI-based quantification analysis of PSMA expression on pre- and post-treatment 68Ga-PSMA11-PETs demonstrate associations with treatment efficacy (PSA response, OS), and associations between patient experience (AEs) and PSMA expression in non-tumor tissues. Expansion of this algorithm to a larger patient cohort may improve our ability to anticipate toxicity by body-wide PSMA detection and predict treatment response. Clinical trial information: NCT03042468.
Collapse
Affiliation(s)
- Jones T. Nauseef
- New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY
| | | | | | | | | | | | | | | | | | | | | | - Dunya Imad
- New York Presbyterian Hospital/Weill Cornell Medical Center, New York, NY
| | | | | | - Cora N. Sternberg
- Englander Institute for Precision Medicine, Weill Cornell Medicine, Hematology/Oncology, New York, NY
| | | | | | | | | | | |
Collapse
|
4
|
Tagawa ST, Sun M, Sartor AO, Thomas C, Singh S, Bissassar M, Fernandez E, Niaz MJ, Ho B, Vallabhajosula S, Babich J, Molina AM, Sternberg CN, Nanus DM, Osborne J, Bander NH. Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.5015] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5015 Background: Antibodies and small molecule ligands target PSMA with different kinetics and biodistribution, with certain sites of PSMA expression such as salivary/lacrimal glands, kidneys, and small bowel less accessible to large antibodies. Alpha emitters such as 225Ac have high potency, but short range. We report dose-escalation plus expansion cohort results of a first in human study of 225Ac-J591. Methods: Men with progressive mCRPC following at least 1 potent AR-pathway inhibitor (ARPI, e.g. abi/enza) and chemo (or unfit/refuse chemo) without limit of # prior therapies (including Ra-223 or prior 177Lu-PSMA) provided adequate organ function were eligible. Baseline 68Ga-PSMA11 PET was performed, but not used for eligibility. Dose-escalation was in single-subjects x4 followed by 3+3 with a single infusion of 225Ac-J591 (13.3 KBq/kg with planned escalation up to 93.3 KBq/kg). Dose-limiting toxicity (DLT) was defined as attributable grade (Gr) 4 heme toxicity or Gr 3/4 non-heme tox. Imaging, genomic, patient-reported outcomes (PRO), and immune correlates embedded. Results: 32 men were treated with a single dose of 225Ac-J591 on 7 dose levels with expansion at the highest dose level (n = 16). Median age 69.5 (range 52-89), PSA 149.1 (4.8-7168.4); 75% with >2 prior ARPI, 62.5% chemo, 28% Ra-223, 43.7% 177Lu-PSMA. One (3.1%) CALGB (Halabi) good prognostic risk, 8 (25%) intermediate, and 23 (71.9%) poor risk. While PSMA uptake was not a prerequisite for treatment, of 28 with pre-treatment PSMA PET, none had tumor SUVmax < liver, 5 (17.8%) with tumor SUVmax 1-2.5x liver, 2 (7.2%) with tumor SUVmax 2.5-5x liver, and 21 (75%) with tumor SUVmax > 5x liver SUVmean. 1 of 6 in cohort 6 (80 KBq/kg) had DLT (Gr 4 anemia and platelets) with 0 of 6 at the highest dose level (93.3 KBq/Kg) and this dose was expanded. High Gr AEs were restricted to hematologic: In addition to DLT, 4 (12.5%) Gr 3 platelets and 2 (6.2%) with Gr 3 neutropenia. Non-heme AE’s were restricted to Gr 1/2 and included: 10 (31.2%) fatigue, 5 (15.6%) pain flare, 14 (43.7%) nausea, 8 (25%) with Gr 1 xerostomia (of which 5 received prior 177Lu-PSMA), 12 (37.5%) AST elevation. Despite prior treatment including 177Lu-PSMA and no selection for PSMA expression, 22 (68.7%) with any PSA decline, 12 (37.5%) with > 50% PSA decline. Of 21 with paired baseline and 12-wk CTC counts, 12 declined (5 converting from unfavorable to favorable and 5 converting detectable to 0), 5 remained 0, 4 increased. In the subset with PRO data, pain scores by BPI-SF tended to improve by wk 12. Following a single dose of 225Ac-J591, median PFS 7.2 months [95% CI 4.6-NR], median OS 10.9 months [7.6-21.1]. Conclusions: PSMA-targeted alpha-emitter 225Ac utilizing intact antibody J591 is tolerable with early evidence of clinical activity. Based upon these results, a follow up study [NCT04506567] testing multiple and fractionated dosing of 225Ac-J591 is underway. Clinical trial information: NCT03276572.
Collapse
|
5
|
Sun M, Nauseef JT, Lebenthal JM, Niaz MJ, Singh S, Chamberlain TA, Bissassar M, Patel A, Tan A, Vallabhajosula S, Babich J, Christos PJ, Osborne J, Molina AM, Sternberg CN, Nanus DM, Bander NH, Tagawa ST. A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.6_suppl.tps188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
TPS188 Background: Prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT) is a promising treatment. PSMA-targeting via large antibodies vs small molecules has different kinetics, biodistribution, and resulting clinical toxicities. Using beta-TRT, 177Lu-J591 has more heme toxicity and 177Lu-PSMA-617 more non-heme toxicity (xerostomia and nausea) [Niaz AUA 2020]. Alpha-emitters are more potent than beta radionuclides, and alpha-PSMA-TRT has efficacy even after beta-PSMA-TRT. In a first-in-human phase I dose-escalation study of 225Ac-J591, patients with mCRPC were treated with a single dose of 225Ac-J591 on seven dose levels, up to 93.3 KBq/kg [Tagawa ASCO 2020]. No maximal tolerated dose (MTD) was achieved. One patient treated at 80 KBq/kg developed dose-limiting toxicity (DLT) of grade 4 anemia and thrombocytopenia, but 0 of 6 at 93.3 KBq/Kg had grade > 3 heme toxicity or grade > 2 non-heme toxicity. Preliminary results indicate 64% had any PSA decline and 41% had > 50% PSA decline (PSA50) across all doses, despite lack of selection for PSMA expression and the majority having been previously treated with 177Lu-PSMA. Methods: Entry criteria include progressive mCRPC by PCWG3 criteria, ECOG PS 0-2, intact organ function (including normal neutrophil and platelet counts), and prior receipt of AR pathway inhibitor and chemotherapy (or refuse/ineligible for chemotherapy). There is no limit to prior lines of therapy except alpha-PSMA-TRT. Phase I includes 2 separate parallel dose-escalation cohorts. In the fractionated-dose cohort, men will receive a single cycle of 225Ac-J591 administered on D1 and D15. In the multiple-dose cohort, 225Ac-J591 will be given every 6 weeks for up to 4 cycles. The phase I component is a 3+3 dose-escalation study design, with the goal of identifying MTD. Each phase II component will treat up to 27 men with PSMA+ PET scans in a Simon 2-stage design with 90% power to exclude the null hypothesis (35% or fewer patients with PSA50). Eligible men with negative PSMA PET scans will be offered treatment with informed consent in an exploratory subgroup, but will not be counted towards phase II efficacy. Secondary outcomes include radiographic response by PCWG modified RECIST 1.1 criteria and PSMA PET, biochemical and radiographic progression-free survival, circulating tumor cell counts, and overall survival. Patient reported outcomes, genomic, and immune analyses are exploratory. Enrollment began in August 2020 (NCT04506567). Clinical trial information: NCT04506567.
Collapse
Affiliation(s)
| | - Jones T. Nauseef
- NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY
| | - Justin M Lebenthal
- New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY
| | | | | | | | | | | | | | | | | | - Paul J. Christos
- Department of Biostatistics and Epidemiology, Weill Cornell Medical College, New York, NY
| | | | | | - Cora N. Sternberg
- Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY
| | | | | | | |
Collapse
|
6
|
Paul DM, Ghiuzeli CM, Rini J, Palestro CJ, Fung EK, Ghali M, Ben-Levi E, Prideaux A, Vallabhajosula S, Popa EC. A pilot study treatment of malignant tumors using low-dose 18F-fluorodeoxyglucose ( 18F-FDG). Am J Nucl Med Mol Imaging 2020; 10:334-341. [PMID: 33329935 PMCID: PMC7724279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 06/23/2020] [Accepted: 10/05/2020] [Indexed: 06/12/2023]
Abstract
Photons, electrons and protons have therapeutic use however positrons have only been used for diagnostic imaging purposes. The energies of positrons (β+) from F-18 (0.633 MeV) and electrons (β-) from I-131 (0.606 MeV) are very close and have similar equilibrium dose constants. Since [18F]-fluorodeoxyglucose (18F-FDG) clears rapidly from circulation, administration of 37-74 GBq (1-2 Ci) of 18F-FDG is relatively safe from an internal radiation dosimetry point of view. We initiated a phase I dose escalation study to assess the safety, toxicity, and potential therapeutic utility of administering 100-200 mCi/m2 18F-FDG delivered over a 1 to 5 day period in patients with advanced lymphomas and solid tumors refractory to standard of care treatment (SCT). Here we report the results of the first four patients treated. Four patients with advanced cancers received a single dose of 3.7-7.4 GBq/m2 (100-200 mCi/m2) 18F-FDG. We monitored the patients for adverse effects and for response. No treatment-related toxicities were observed. There was no increased radiation exposure to personnel. Two patients showed decrease in the index lesions' SUVs by 17-33% (Day 1) and 25-31% (Day 30) post treatment. The two other patients showed stable disease on 18F-PET-CT. Interestingly, responses were seen at low radiotherapy doses (below 1 Gy). This exploratory study demonstrated the safety of therapeutic administration of up to 14.2 GBq (385 mCi) 18F-FDG. In patients with 18F-FDG-avid cancers, targeted radionuclide 18F-FDG therapy appears safe and may offer clinical benefit.
Collapse
Affiliation(s)
- Doru M Paul
- Medical Oncology, Weill Cornell Medical College (WCMC)New York, NY, USA
| | | | | | | | | | - Maged Ghali
- Radiation Oncology, Northwell HealthLake Success, NY, USA
| | | | | | | | - Elizabeta C Popa
- Medical Oncology, Weill Cornell Medical College (WCMC)New York, NY, USA
| |
Collapse
|
7
|
Christopher S, Tadlock BA, Veroneau BJ, Harnish C, Perera NKP, Knab AM, Vallabhajosula S, Bullock GS. Epidemiological profile of pain and non-steroid anti-inflammatory drug use in collegiate athletes in the United States. BMC Musculoskelet Disord 2020; 21:561. [PMID: 32814544 PMCID: PMC7437034 DOI: 10.1186/s12891-020-03581-y] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Accepted: 08/10/2020] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Although athletic endeavours are associated with a high amount of physical stress and injury, the prevalence of pain is underreported in the sports medicine literature with only a few studies reporting pain on collegiate athletes or exploring sex difference of pain. Impact of pain on athlete availability, training and performance can be mitigated when key epidemiological information is used to inform adequate pain management strategies. This study aims to 1) provide an epidemiological profile of self-reported pain experienced by the National Collegiate Athletic Association (NCAA) athletes by sex during the first half of the 2019 season, 2) describe their self-reported non-steroidal anti-inflammatory drug (NSAID) use. METHODS Online survey was completed by athletes at three NCAA institutions from 1 August to 30 September 2019. Descriptive statistics were used to describe player demographic data, self-reported pain and self-reported NSAID use. Pain incidence proportion were calculated. RESULTS Two hundred thirty female athletes and 83 male athletes completed the survey. Self-reported pain incidence proportion for female athletes was 45.0 (95% CI 41.5-48.5) vs 34.9 (95% CI 29.4-40.4) for male athletes. Majority of the athletes did not report pain (55% female vs 62% male) during the first half of the 2019 season. Female athletes reported pain in their back (35%), knee (26%), and ankle/foot (23%) whilst male athletes reported pain in their knee (35%), back (28%), and shoulder (24%). Of all athletes, 28% female vs 20% male athletes reported currently taking NSAIDs. Of athletes that reported pain, 46% female vs 38% male athletes currently took NSAIDs. 70% female vs 61% male athletes self-purchased NSAIDs, and 40% female vs 55% male athletes consumed alcohol. CONCLUSIONS Half of female athletes and one in three male athletes reported pain. Most commonly back, knee and foot/ankle pain and knee, back and shoulder pain was reported in female and male athletes respectively. One in four female athletes and one in five male athletes use NSAIDs for pain or prophylactic purpose. Majority self-purchase these medications indicating need for health literacy interventions to mitigate potential adverse effects.
Collapse
Affiliation(s)
- S Christopher
- Department of Physical Therapy Education, Elon University, Elon, NC, USA
| | - B A Tadlock
- Department of Physical Therapy Education, Elon University, Elon, NC, USA
| | - B J Veroneau
- Department of Physical Therapy Education, Elon University, Elon, NC, USA
| | - C Harnish
- Department of Exercise Science, Mary Baldwin College, Staunton, VA, USA
| | - N K P Perera
- Centre for Sport, Exercise and Osteoarthritis Research Versus Arthritis, University of Oxford, Oxford, UK.,Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, B4495, Oxford, OX3 7LD, UK.,Unit of Physiotherapy, Department of Health, Medicine and Caring Sciences (HMV), Linköping University, Linköping, Sweden.,School of Allied Health, Human Services and Sport, Latrobe University, Melbourne, Victoria, Australia
| | - A M Knab
- Kinesiology Department, Queens University of Charlotte, Charlotte, NC, USA
| | - S Vallabhajosula
- Department of Physical Therapy Education, Elon University, Elon, NC, USA
| | - G S Bullock
- Centre for Sport, Exercise and Osteoarthritis Research Versus Arthritis, University of Oxford, Oxford, UK. .,Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, B4495, Oxford, OX3 7LD, UK. .,Department of Orthopaedic Surgery, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
| |
Collapse
|
8
|
Tagawa ST, Osborne J, Thomas C, Fernandez E, Niaz MJ, Vallabhajosula S, Vlachostergios P, Molina AM, Sternberg C, Singh S, Patel A, Tan A, Babich J, Nanus DM, Ballman K, Bander NH. Abstract CT122: Phase I dose-escalation study of prostate-specific membrane antigen (PSMA)-targeted alpha emitter 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC). Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-ct122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: PSMA may be targeted by antibodies or small molecule ligands labeled with potent alpha emitters. Certain sites of PSMA expression such as salivary/lacrimal glands, kidneys, and small bowel are not accessible to antibodies such as J591. Following binding, immunoreactivity, and xenograft studies, we performed a first in human study of 225Ac-J591.
Methods: Men with progressive mCRPC following at least 1 potent AR-targeted agent (e.g. abiraterone/enzalutamide) and taxane chemotherapy (or unfit/refuse chemo) without limit of # prior therapies (including radium-223 or prior PSMA therapy) provided adequate organ function were eligible. Baseline 68Ga-PSMA11 PET was performed, but not used for eligibility. Initially single-subject cohorts were treated until transition to 3+3 with dose level 5 (the dose level predicted by historical J591 dosimetry to have moderate toxicity) with a single infusion of 225Ac-J591 (13.3 KBq/kg with planned escalation up to 93.3 KBq/kg). Dose-limiting toxicity (DLT) was defined as attributable grade 4 hematologic toxicity or grade 3/4 non-heme toxicity. Imaging, genomic, patient-reported outcomes, and immune correlates are included.
Results: In the dose-escalation phase, 22 men were treated on 7 dose levels; median age 72.5 (range 58-89), PSA 146.5 (4.8-7168.4); 82% with at least 2 prior potent AR pathway inhibitors, 64% chemo, 23% radium-223, 55% prior 177Lu-PSMA. 1 (4.5%) CALGB (Halabi) good prognostic risk, 10 (20.7%) intermediate, and 11 (50%) poor prognostic risk category. One of 6 subjects in cohort 6 (80 KBq/kg) had DLT (grade 4 anemia and platelets); no other subjects had any attributable grade >2 non-hematologic or grade >3 heme AE (including 0 of 6 at the highest dose level 93.3 KBq/Kg). Low grade temporary AE's include: 17 (77%) with fatigue, 11 (50%) pain flare, 11 (50%) nausea, 6 (27%) with Gr 1 xerostomia (5 of 6 with prior 177Lu-PSMA), 4 (18%) AST elevation. Despite the heavily pre-treated population including the majority with prior PSMA-TRT and no selection for PSMA expression, 14 (63.6%) with any PSA decline, 9 (40.9%) with >50% PSA decline. Interestingly, 15 (68%) had initial PSA increase followed by subsequent decline from peak (delayed effect). With follow up ongoing 2 with response > 1 year despite prior 177Lu-PSMA with correlative assays in process. Of 15 with paired baseline and 12-week CTC counts (CellSearch), 8 declined (45-100% decline), 4 remained undetectable, 3 increased.
Conclusions: PSMA-targeted alpha-emitter 225Ac utilizing intact antibody J591 is tolerable with early evidence of clinical activity including long-term responders in a pre-treated population. Correlative studies are in progress and enrollment into a Simon 2-stage expansion cohort has been initiated. Clinicaltrials.gov NCT03276572
Citation Format: Scott T. Tagawa, Joseph Osborne, Charlene Thomas, Escarleth Fernandez, Muhammad J. Niaz, Shankar Vallabhajosula, Panagiotis Vlachostergios, Ana M. Molina, Cora Sternberg, Sharon Singh, Amie Patel, Angela Tan, John Babich, David M. Nanus, Karla Ballman, Neil H. Bander. Phase I dose-escalation study of prostate-specific membrane antigen (PSMA)-targeted alpha emitter 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC) [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT122.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Amie Patel
- Weill Cornell Medical College, New York, NY
| | - Angela Tan
- Weill Cornell Medical College, New York, NY
| | | | | | | | | |
Collapse
|
9
|
Tagawa ST, Osborne J, Fernandez E, Thomas C, Niaz MJ, Ciriaco A, Vallabhajosula S, Vlachostergios PJ, Molina AM, Sternberg CN, Singh S, Babich J, Nanus DM, Ballman KV, Bander NH. Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.5560] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5560 Background: Antibodies (Abs) or small molecules can target PSMA with different biodistribution. Certain sites of PSMA expression (e.g. salivary/lacrimal glands, kidneys, small bowel) are not accessible to Abs. Given radiosensitivity of PC and potency of alpha emitters plus the ability to minimize targeting off tumor PSMA+ sites with J591, we performed a 1st in human study of 225Ac-J591. Methods: Men with progressive mCRPC following at least 1 potent AR-pathway inhibitor (ARPI) and chemo (or unfit/refuse) without limit of # prior therapies (Ra-223 and 177Lu-PSMA allowed) with ECOG PS 0-2 and adequate organ function were eligible. Baseline 68Ga-PSMA11 PET was performed, but not used for eligibility. Initially 1-subject cohorts treated until transition to 3+3 at dose level 5 (predicted by dosimetry to have moderate toxicity) with a single infusion of 225Ac-J591 (13.3 KBq/kg with planned escalation up to 93.3 KBq/kg). Dose-limiting toxicity (DLT) defined as attributable grade (Gr) 4 heme toxicity or Gr 3/4 non-heme tox. Imaging, genomic, patient-reported outcomes (PRO), and immune correlates embedded. Results: 22 men treated on 7 dose levels; median age 72.5 (range 58-89), PSA 147 (5-7168); 82% with >2 prior ARPI, 64% chemo, 23% Ra-223, 55% 177Lu-PSMA. 1 (5%) CALGB (Halabi) good prognostic risk, 10 (45%) intermed, 11 (50%) poor risk. 1 of 6 in cohort 6 (80 KBq/kg) had DLT (Gr 4 anemia and platelets); no others had attributable Gr > 2 non-heme or Gr > 3 heme AE (including 0 of 6 at the highest dose level 93.3 KBq/Kg). Gr 1/2 AE’s: 17 (77%) fatigue, 11 (50%) pain flare, 10 (45%) anemia (+1 Gr 3), 10 (45%) platelets, 6 (27%) nausea, 6 (27%) xerostomia (5 of 6 with prior 177Lu-PSMA), 5 (23%) neutropenia, 4 (18%) AST elevation. Despite prior treatment including 177Lu-PSMA and no selection for PSMA expression, 14 (64%) with any PSA decline, 9 (41%) with > 50% PSA decline. 15 (68%) had initial PSA rise followed by decline from peak (delayed effect). 2 with response > 1 year despite prior 177Lu-PSMA. Of 15 with paired baseline and 12-wk CTC counts, 8 declined, 4 remained undetectable, 3 increased. In subset with complete PRO data (baseline to 12 wks), pain was improved or absent by BPI-SF in 63% and by FACT-P in 89%. Social and emotional well-being domains of FACT-P improved or stabilized in majority; physical well-being improved in most responders. Conclusions: Alpha-emitter 225Ac targeting PSMA via J591 Ab is tolerable with early evidence of clinical activity in a pre-treated population with favorable PRO’s. Enrollment to expansion cohort being completed. Clinical trial information: NCT03276572 .
Collapse
|
10
|
Verma A, Hesterman JY, Chazen JL, Holt R, Connolly P, Horky L, Vallabhajosula S, Mozley PD. Intrathecal 99mTc-DTPA imaging of molecular passage from lumbar cerebrospinal fluid to brain and periphery in humans. Alzheimers Dement (Amst) 2020; 12:e12030. [PMID: 32355870 PMCID: PMC7191108 DOI: 10.1002/dad2.12030] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/24/2019] [Revised: 03/01/2020] [Accepted: 03/11/2020] [Indexed: 12/12/2022]
Abstract
INTRODUCTION Cerebrospinal fluid (CSF) molecular exchange with brain interstitial fluid (ISF) and periphery is implicated in neurological disorders but needs better quantitative clinical assessment approaches. METHODS Following intrathecal (ITH) dosing via lumbar puncture, Technetium-99 m (99mTc-) diethylenetriaminepentaacetic acid (DTPA) imaging was used to quantify neuraxial spread, CSF-brain molecular exchange, and CSF-peripheral clearance in 15 normal human volunteers. The effect of experimental convection manipulation on these processes was also assessed. RESULTS Rostral cranial 99mTc-DTPA exposures were influenced by the volume of artificial CSF in the formulation. Signal translocation to the cranial cisterns and the brain parenchyma was observable by 3 hours. 99mTc-DTPA penetrated cortical ISF but showed lower signal in deeper structures. Urinary 99mTc-DTPA signal elimination was accelerated by higher formulation volumes and mechanical convection. DISCUSSION Widely used for detecting CSF leaks, ITH 99mTc-DTPA imaging can also become a useful clinical biomarker for measuring molecular exchange physiology between the CSF, brain, and periphery.
Collapse
Affiliation(s)
- Ajay Verma
- Codiak BiosciencesCambridgeMassachusetts
| | | | - J. Levi Chazen
- Cornell University Weill College of MedicineNew YorkNew York
| | | | | | | | | | - P. David Mozley
- Cornell University Weill College of MedicineNew YorkNew York
| |
Collapse
|
11
|
Niaz* MJ, Skafida M, Osborne J, Nanus D, Molina A, Thomas C, Vallabhajosula S, Christos P, Bander N, Tagawa S. PD16-11 COMPARISON OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED RADIONUCLIDE THERAPY (TRT) WITH LUTETIUM-177 (
177
LU) VIA ANTIBODY J591 VS SMALL MOLECULE LIGAND PSMA-617. J Urol 2020. [DOI: 10.1097/ju.0000000000000859.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
12
|
Tagawa ST, Osborne J, Niaz MJ, Vallabhajosula S, Vlachostergios PJ, Thomas C, Molina AM, Sternberg CN, Singh S, Fernandez E, Babich J, Nanus DM, Ballman KV, Bander NH. Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.6_suppl.114] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
114 Background: Prostate-specific membrane antigen (PSMA) can be targeted by antibodies (Ab) or small molecule ligands labeled with potent α emitters (e.g. 225Ac). Unlike ligands, Ab biodistribution does not include non-tumor organs such as the salivary glands, kidneys and small bowel. We performed a phase I single ascending dose Ab study. Methods: Eligibility: progressive mCRPC following at least 1 potent AR pathway inhibitor (ARPI; e.g. abi/enza) and docetaxel (or unfit/refuse chemo) without limit of # prior therapies provided adequate organ function. Baseline 68Ga-PSMA11 PET was performed but not used for eligibility. Single-subject cohorts received a single infusion of 225Ac-J591 until grade (Gr) > 1 attributable toxicity or dose level 5, then transition to 3+3 design. Cohort 1 = 13.3 KBq/kg with planned escalation up to dose level 7 (93.3 KBq/kg). Dose-limiting toxicity (DLT) defined as attributable Gr 4 heme or Gr 3/4 non-heme toxicity. Results: 22 men were treated on 7 dose levels; median age 72.5 (range 58-89), PSA 146.5 (4.8-7168.4); 82% with >2 prior ARPI, 64% chemo, 45% sipuleucel-T, 23% radium-223, 55% prior 177Lu-PSMA. By standard imaging 82% bone, 36% lymph node, 9% liver mets. At the time of data cutoff, 1 of 6 men in cohort 6 (80 KBq/kg) had DLT (Gr 4 anemia and platelets); he had 4 prior cycles of 177Lu-PSMA. No other attributable Gr >2 non-hematologic or Gr >3 heme AE (including 0 of 6 at the highest dose level). Low Gr temporary AE’s include: 16 (73%) with fatigue, 11 (50%) pain, 11 (50%) nausea, 6 (27%) with xerostomia (5 of 6 with prior 177Lu-PSMA), 3 (14%) AST elevation. With follow-up ongoing, 60% with any PSA decline, 35% with >50% PSA decline. Of 10 with detectable baseline and 12-week CTC counts (CellSearch), 8 declined (45-100% decline); 5 (50%) with CTC count conversion. While PSMA uptake was not a prerequisite for treatment, all had some PSMA uptake on 68Ga-PSMA11 PET/CT; 64% with SUVmax >5x liver SUV, 14% 2.5x – 5x liver, and 23% with SUVmax 0-2.5x liver SUV. Conclusions: PSMA-targeted alpha-emitter 225Ac utilizing intact Ab J591 is well tolerated with early evidence of clinical activity in a pre-treated population, including the majority with prior 177Lu-PSMA. Clinical trial information: NCT03276572.
Collapse
|
13
|
Vlachostergios PJ, Goswami S, Niaz MJ, Thomas C, Christos PJ, Osborne J, Vallabhajosula S, Molina AM, Sternberg CN, Singh S, Tan A, Patel A, Nanus DM, Bander NH, Tagawa ST. Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.6_suppl.45] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
45 Background: We performed the 1st dose-escalation study of PSMA-targeted radionuclide therapy with 177Lu-PSMA-617. Using dose-fractionation, we intended to deliver a dose-intense regimen designed to minimize radioresistance due to repopulation. Radionuclide therapy may be able to treat symptoms due to tumor and therefore may be associated with improvement in PRO. Methods: Inclusion: progressive mCRPC following potent AR-pathway inhibitor (ARPI, e.g. abi/enza) and taxane (or unfit/refuse chemo) without limit of # prior therapies, adequate organ function, ECOG performance status 0-2, without preselection for PSMA expression. Treatment was a single cycle of fractionated dose 177Lu-PSMA-617 on D1 and D15 (7.4 to 22 GBq in phase 1; 22.2 GBq in phase 2). PRO tools included FACT-P and BPI-SF at baseline and follow up. Results: 44 men with median age 69 (range 55-91), median PSA 182.97 (range 0.89-5541) were treated. 93% with bone, 45% nodal, 18% lung, 9% liver, 9% other visceral metastases. 55% with at least 1 prior chemo regimen, 52% >2 prior ARPI, 27% with Ra223, 30% sip-T, 5% 177Lu-J591. 59.1% with >50% PSA decline (66.7% at 22.2 GBq, n=21), median overall survival 16 months (95% CI 11-NR). High grade (Gr) toxicity was rare with 6.8% Gr 3 anemia and 2.3% Gr 3 platelets. Gr 1/2 treatment-emergent AE’s include 81.8% with pain flare, 61.4% xerostomia, 29.5% fatigue, 25% platelets, 25% anemia, 25% pain, 15.5% nausea. FACT-P scores tended to improve in all categories by D22 (1 week later), with overall FACT-P scores improving by mean of 8.9 points (p=0.07) at D22 and remaining improved at 12 wks. All BPI scores also improved, with BPI overall severity score improving by mean of 3.0 at D22 (p=0.008) and remained better than baseline at 12 wks. There was no clear association with any AE and PRO changes, but those with PSA decline tended to have improved pain scores (p=0.1). Conclusions: A single cycle of up to 22.2 GBq of 177Lu-PSMA-617 is safe with fractionated (D1 & D15) dosing, with encouraging early efficacy signals in a population unselected for PSMA expression and improved quality of life and pain scores by validated PRO instruments. Clinical trial information: NCT03042468.
Collapse
Affiliation(s)
| | | | | | | | - Paul J. Christos
- Department of Biostatistics and Epidemiology, Weill Cornell Medical College, New York, NY
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Niaz MJ, Batra JS, Walsh RD, Ramirez-Fort MK, Vallabhajosula S, Jhanwar YS, Molina AM, Nanus DM, Osborne JR, Bander NH, Tagawa ST. Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 ( 177 Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. Oncologist 2020; 25:477-e895. [PMID: 31999003 DOI: 10.1634/theoncologist.2020-0028] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2019] [Accepted: 01/13/2020] [Indexed: 11/17/2022] Open
Abstract
LESSONS LEARNED Hyperfractionation of lutetium-177 (177 Lu)-J591 for patients with metastatic castration-resistant prostate cancer did not appear to have any additional advantage over the single dose 177 Lu-J591 or fractionated two-dose 177 Lu-J591 therapy. Definite conclusions were challenging because of the small sample size of this study, and so further studies are needed to evaluate the viability of the hypothesis. On the basis of available data, a registration study of 177 Lu-J591 (also known as TLX591) is planned and will use the two-dose fractionation schedule (Telix Pharma Q3 2019 update https://telixpharma.com/news-media/). BACKGROUND Phase I and II single-dose studies of lutetium-177 (177 Lu)-J591, a radio-labeled antibody binding prostate-specific membrane antigen (PSMA), demonstrated safety and efficacy with dose response. Modest dose fractionation of 177 Lu-J591 (2 doses) has less myelosuppression per similar cumulative dose, allowing higher doses to be administered safely. We hypothesized that additional dose fractionation would allow a higher cumulative dose, potentially with less toxicity and more efficacy. METHODS Men with progressive metastatic castration-resistant prostate cancer and adequate organ function were enrolled. 177 Lu-J591 was administered at 25 mCi/m2 every 2 weeks until the emergence of related grade 2 toxicity. 177 Lu-J591 imaging was performed and circulating tumor cell (CTC) counts were measured before and after treatment along with standard monitoring. RESULTS Six subjects in a single cohort, with a median age of 68.6 years, were enrolled. Patients received three to six doses (cumulative 75-150 mCi/m2 ). Two (33%) patients had >30% prostate-specific antigen (PSA) decline and three (50%) had CTC count decline. Two (33%) experienced grade (Gr) 4 neutropenia (without fever), three (50%) had Gr 4 thrombocytopenia (without hemorrhage), and two (33%) required platelet transfusions. Following hematological improvement, two patients developed worsening cytopenia during prostate cancer progression; bone marrow biopsies revealed infiltrative tumor replacing normal marrow elements without myelodysplasia. Targeting of known disease sites was seen on planar imaging in all. CONCLUSION Hyperfractionation of 177 Lu-J591 is feasible but does not seem to have significant advantages over the two-dose fractionation regimen.
Collapse
Affiliation(s)
| | - Jaspreet S Batra
- Department of Urology, Weill Cornell Medical College, New York, USA
| | - Ryan D Walsh
- Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, USA
| | - Marigdalia K Ramirez-Fort
- Department of Urology, Weill Cornell Medical College, New York, USA
- Department of Physiology/Pathology, San Juan Bautista School of Medicine, Caguas, Puerto Rico
| | - Shankar Vallabhajosula
- Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medical College, New York, USA
| | - Yuliya S Jhanwar
- Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medical College, New York, USA
| | - Ana M Molina
- Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, USA
- Meyer Cancer Center, New York, USA
| | - David M Nanus
- Department of Urology, Weill Cornell Medical College, New York, USA
- Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, USA
- Meyer Cancer Center, New York, USA
| | - Joseph R Osborne
- Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medical College, New York, USA
- Meyer Cancer Center, New York, USA
| | - Neil H Bander
- Department of Urology, Weill Cornell Medical College, New York, USA
- Meyer Cancer Center, New York, USA
| | - Scott T Tagawa
- Department of Urology, Weill Cornell Medical College, New York, USA
- Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, USA
- Meyer Cancer Center, New York, USA
| |
Collapse
|
15
|
Andrews AW, Vallabhajosula S, Ramsey C, Smith M, Lane MH. Reliability and normative values of the Wheelchair Propulsion Test: A preliminary investigation. NeuroRehabilitation 2020; 45:229-237. [PMID: 31498140 DOI: 10.3233/nre-192779] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Normative data for the equivalent of gait speed via the Wheelchair Propulsion Test (WPT) do not exist for wheelchair users. OBJECTIVE The purposes of the current study were to: 1) determine the reliability of the WPT, 2) propose and compare normative values for the WPT for young adult males and females utilizing three different propulsion techniques, and 3) compare how different wheelchair types affect performance on the WPT. METHODS 50 young adults (25 of each sex) performed the WPT using three different propulsion techniques in three different types of wheelchairs. Participants were asked to propel a wheelchair over 10 m at a comfortable speed. Time and number of pushes were recorded for three trials for each propulsion technique in each type of wheelchair. RESULTS All of the ICC(2,2) values were >0.83 for speed and number of pushes. Normative values for speed, number of pushes, push frequency and effectiveness categorized by propulsion technique, sex and wheelchair type were developed. CONCLUSIONS Preliminary normative values have been established for young adults performing the WPT. This study highlights the need to maintain consistency of the wheelchair type and propulsion technique between trials in order for the WPT to be reliable.
Collapse
Affiliation(s)
- A W Andrews
- Department of Physical Therapy Education, Elon University, Elon, NC, USA
| | - S Vallabhajosula
- Department of Physical Therapy Education, Elon University, Elon, NC, USA
| | - C Ramsey
- Department of Physical Therapy Education, Elon University, Elon, NC, USA
| | - M Smith
- OhioHealth, Columbus, OH, USA
| | - M H Lane
- Wilson Medical Center, Wilson, NC, USA
| |
Collapse
|
16
|
Tagawa S, Osborne J, Hackett A, Niaz M, Cooley V, Christos P, Vlachostergios P, Thomas C, Gracey L, Beltran H, Molina A, Nanus D, Babich J, Vallabhajosula S, Sartor O, Ballman K, Bander N. Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz248.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Kelly J, Amor-Coarasa A, Ponnala S, Thiele N, Nikolopoulou A, Williams C, Wilson J, Vallabhajosula S, Babich J. A comparison of chelate labeling with Ac-225: application to PSMA-targeting radiopharmaceuticals. Nucl Med Biol 2019. [DOI: 10.1016/s0969-8051(19)30220-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
18
|
Kreisl WC, Jin P, Lee S, Dayan ER, Vallabhajosula S, Pelton G, Luchsinger JA, Pradhaban G, Devanand DP. Odor Identification Ability Predicts PET Amyloid Status and Memory Decline in Older Adults. J Alzheimers Dis 2019; 62:1759-1766. [PMID: 29614678 DOI: 10.3233/jad-170960] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
BACKGROUND Odor identification deficits occur in Alzheimer's disease (AD), as measured by the 40-item University of Pennsylvania Smell Identification Test (UPSIT). OBJECTIVE To determine if UPSIT scores predict amyloid-β (Aβ) status, determined by 11C-Pittsburgh Compound B PET. We also compared UPSIT scores to Aβ status in predicting future memory decline. METHODS Subjects were recruited into a longitudinal clinical prediction study. We analyzed data from those who had UPSIT, cognitive testing, PIB PET, and at least 12 months' clinical follow-up. Forty-six amnestic mild cognitive impairment patients and 25 cognitively normal controls were included. Amyloid-positivity was defined as composite PIB standardized uptake value ratio >1.5. Logistic regression and Receiver Operating Characteristic Curve analyses tested the predictive utility of impaired olfaction (defined as UPSIT score <35) and amyloid-positivity for memory decline. RESULTS High UPSIT scores predicted absence of amyloidosis on PET, with negative predictive value of 100%. Positive predictive value of low UPSIT scores on positive Aβ status was only 41%. Both low UPSIT score (OR = 4.301, 95% CI = 1.248, 14.821, p = 0.021) and positive PET scan (OR = 20.898, 95% CI = 2.222, 196.581, p = 0.008) predicted memory decline. CONCLUSION Individuals with high UPSIT scores are less likely to have cerebral amyloidosis or experience memory decline. Therefore, UPSIT has potential as a screening tool to determine utility of Aβ PET in clinical practice or enrollment in clinical trials. Low UPSIT score is a non-specific marker of neurodegeneration that could indicate further workup in patients with memory complaints.
Collapse
Affiliation(s)
| | - Peng Jin
- Division of Biostatistics, Columbia University Medical Center, New York, NY, USA
| | - Seonjoo Lee
- Division of Biostatistics, Columbia University Medical Center, New York, NY, USA
| | - Ezra R Dayan
- Taub Institute, Columbia University Medical, New York, NY, USA
| | | | - Gregory Pelton
- Department of Psychiatry, Columbia University Medical Center, New York, NY, USA
| | - José A Luchsinger
- Departments of Medicine and Epidemiology, Columbia University Medical Center, New York, NY, USA
| | | | - D P Devanand
- Department of Psychiatry, Columbia University Medical Center, New York, NY, USA
| |
Collapse
|
19
|
Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, Osborne J, Beltran H, Molina AM, Goldsmith SJ, Bander NH, Nanus DM. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ( 177 Lu-J591) for metastatic castration-resistant prostate cancer. Cancer 2019; 125:2561-2569. [PMID: 31012963 DOI: 10.1002/cncr.32072] [Citation(s) in RCA: 76] [Impact Index Per Article: 15.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2018] [Revised: 02/07/2019] [Accepted: 02/11/2019] [Indexed: 12/15/2022]
Abstract
BACKGROUND Prostate cancer is radiosensitive. Prostate-specific membrane antigen (PSMA) is selectively overexpressed on advanced, castration-resistant tumors. Lutetium-177-labeled anti-PSMA monoclonal antibody J591 (177 Lu-J591) targets prostate cancer with efficacy and dose-response/toxicity data when delivered as a single dose. Dose fractionation may allow higher doses to be administered safely. METHOD Men with metastatic castration-resistant prostate cancer refractory to or refusing standard treatment options with normal neutrophil and platelet counts were enrolled in initial phase 1b dose-escalation cohorts followed by phase 2a cohorts treated at recommended phase 2 doses (RP2Ds) comprising 2 fractionated doses of 177 Lu-J591 2 weeks apart. 177 Lu-J591 imaging was performed after treatment, but no selection for PSMA expression was performed before enrollment. Phase 2 patients had circulating tumor cell (CTC) counts assessed before and after treatment. RESULTS Forty-nine men received fractionated doses of 177 Lu-J591 ranging from 20 to 45 mCi/m2 ×2 two weeks apart. The dose-limiting toxicity in phase 1 was neutropenia. The RP2Ds were 40 mCi/m2 and 45 mCi/m2 ×2. At the highest RP2D (45 mCi/m2 ×2), 35.3% of patients had reversible grade 4 neutropenia, and 58.8% of patients had thrombocytopenia. This dose showed a greater decrease in prostate-specific antigen (PSA) levels and longer survival (87.5% with any PSA decrease, 58.8% with >30% decrease, 29.4% with >50% decrease; median survival, 42.3 months [95% confidence interval, 19.9-64.7]). Fourteen of 17 (82%) patients with detectable CTCs experienced a decrease in CTC count. Overall, 79.6% of patients had positive PSMA imaging; those with less intense PSMA imaging tended to have poorer responses. CONCLUSION Fractionated administration of 177 Lu-J591 allowed higher cumulative radiation dosing. The frequency and depth of PSA decrease, overall survival, and toxicity (dose-limiting myelosuppression) increased with higher doses.
Collapse
Affiliation(s)
- Scott T Tagawa
- Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York.,Department of Urology, Weill Cornell Medicine, New York, New York.,Meyer Cancer Center, Weill Cornell Medicine, New York, New York
| | - Shankar Vallabhajosula
- Division of Nuclear Medicine, Department of Radiology, Weill Cornell Medicine, New York, New York
| | - Paul J Christos
- Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, New York.,Meyer Cancer Center, Weill Cornell Medicine, New York, New York
| | - Yuliya S Jhanwar
- Division of Nuclear Medicine, Department of Radiology, Weill Cornell Medicine, New York, New York
| | - Jaspreet S Batra
- Department of Urology, Weill Cornell Medicine, New York, New York
| | - Linda Lam
- Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York
| | - Joseph Osborne
- Division of Nuclear Medicine, Department of Radiology, Weill Cornell Medicine, New York, New York
| | - Himisha Beltran
- Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York.,Meyer Cancer Center, Weill Cornell Medicine, New York, New York.,Dana Farber Cancer Institute, Boston, Massachusetts
| | - Ana M Molina
- Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York.,Meyer Cancer Center, Weill Cornell Medicine, New York, New York
| | - Stanley J Goldsmith
- Division of Nuclear Medicine, Department of Radiology, Weill Cornell Medicine, New York, New York
| | - Neil H Bander
- Department of Urology, Weill Cornell Medicine, New York, New York.,Meyer Cancer Center, Weill Cornell Medicine, New York, New York
| | - David M Nanus
- Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, New York.,Department of Urology, Weill Cornell Medicine, New York, New York.,Meyer Cancer Center, Weill Cornell Medicine, New York, New York
| |
Collapse
|
20
|
Niaz MJ, Jhanwar Y, Flynn T, Vallabhajosula S, Khani F, Robinson BD, Tagawa ST, Bander NH, Scherr D. Pilot study of dual imaging with 89Zr-IAB2M and 68Ga-PSMA-11 PET/CT prior to prostatectomy. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.7_suppl.90] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
90 Background: Due to high expression of Prostate Specific Membrane Antigen (PSMA), it’s an excellent candidate for targeted molecular imaging. 89Zr-df-IAB2M is a J591 antibody derived minibody and 68Ga-PSMA-11 is a PSMA small molecule. Methods: Patients with clinically significant (defined as: ≥ 0.5 cm3 with Gleason pattern ≥ 4) localized prostate cancer (PCa) on conventional imaging modalities who planned to undergo surgery were imaged by PET/CT 1-3 hours after 5±2mCi of 68Ga-PSMA-11 injection and 89Zr-IAB2M PET 2-4 days after 10mg IAB2M labeled with 2.5 mCi of 89Zr injection. Image results were interpreted by a central reader without knowledge of the surgical pathology, mapped and the mapped findings later compared with surgical pathology map. Results: 9 patients having clinically localized PCa with median age 65 (46-79) and PSA 8.42 (1.6-12.2) were enrolled. All dominant PCa lesions, which had a median Gleason score 8 (6-9), were detected by both IAB2M and PSMA-11. The smallest of these dominant lesions was 8mm in size. Median SUVmax for dominant lesions was 3.3 (2.3-7.5) on IAB2M and 7.1 (1.6-23.2) on PSMA-11; median MR PIRADS was 4 (4-5). Of 9 Gleason 6 lesions identified on pathology, PSMA-11 detected 3 and IAB2M detected 2. Four extra-prostatic lesions in one patient were detected by both PET agents, 3 were confirmed by surgical pathology and 1 confirmed on bone scan 2 months post-op. A total of 8 lesions reported on scans were not reported by path: 3 were false positive on both scans, 3 were false positive on IAB2M scan only and 2 were false positive on PSMA-11 scan only. 5 Gleason 6 and 2 Gleason 3+4 lesions on pathology were missed by both PET agents and could be considered false negatives. Conclusions: In this small pilot series, performance of the both PET agents was very similar. An advantage of IAB2M is its hepatobiliary clearance rather than renal/urinary, which makes it potentially easier to visualize the PCa and/or pelvic disease; an advantage of PSMA-11 is the ability to image within 1 hour. Clinical trial information: NCT03675451.
Collapse
Affiliation(s)
| | | | | | | | | | - Brian D. Robinson
- Department of Pathology & Laboratory Medicine, Englader Institute for Precision Medicine, Weill Cornell Medical College & New York-Presbyterian Hospital, New York, NY
| | | | | | - Douglas Scherr
- Department of Urology, Weill Cornell Medical College & New York-Presbyterian Hospital, New York, NY
| |
Collapse
|
21
|
Tagawa ST, Niaz MJ, Osborne J, Vallabhajosula S, Beltran H, Harshman LC, Nanus DM, Molina AM, Faltas BM, Hackett A, Gracey L, Sreekumar J, Babich J, Ballman KV, Bander NH. Phase I/II dose-escalation trial of fractionated dose 177Lu-J591 plus 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.7_suppl.tps339] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
TPS339 Background: PC is a radiosensitive disease. PSMA is selectively overexpressed in advanced PC with upregulation by androgen receptor (AR) pathway dysregulation; limited expression exists in other organs. Prior studies of beta-emitting radiolabeled anti-PSMA antibody J591 demonstrated accurate targeting, efficacy with dose-response effect, and safety with predictable dose-limiting myelosuppression. Recent prospective trials have shown efficacy and safety of 177Lu-PSMA-617 in mCRPC. Studies demonstrate different binding sites of J591 and PSMA-617 and co-administration leads to non-competitive additive binding and delivery of payloads to PSMA+ cells. As the pharmacokinetics and biodistribution of the 2 agents is mostly non-overlapping (other than tumor) and given our prior dose-response data, we hypothesize that delivery of the combination will yield higher tumor delivery with less off-target toxicity (i.e. better responses without increased toxicity). Methods: Men with progressive mCRPC following at least 1 potent AR-targeted agent (e.g. abi/enza) and docetaxel (or unfit/refuse chemo) with metastatic disease on CT/MRI or bone scan without limit of # prior therapies (excluding bone-targeted beta-emitting radioisotopes) provided adequate organ function will be enrolled. Pre-treatment 88Ga-PSMA-11 will be performed, but results are not used for eligibility. Treatment includes fractionated 177Lu-J591 at a fixed moderate dose with escalating doses of 177Lu-PSMA-617 (7.4 – 18.5 GBq per cycle, fractionated D1 and D15) in a 3+3 dose-escalation study. Dose-limiting toxicity (DLT) is defined as attributable grade > 3 heme toxicity or grade > 2 non-heme toxicity. Following determination of recommended phase 2 dose (RP2D), the phase 2 portion will enroll in a 2-stage design. Primary endpoints: DLT and RP2D (ph 1) and PSA decline proportion (ph 2). Secondary endpoints include toxicity, radiographic response, PFS, rPFS, OS, CTC count changes. Correlatives include baseline/follow up PSMA imaging, whole body distribution of 177Lu, tissue and circulating genomic assessment, immunologic assessment, and patient reported outcomes (FACT-P and BPI-SF). Clinical trial information: NCT03545165.
Collapse
Affiliation(s)
- Scott T. Tagawa
- Division of Hematology & Medical Oncology, Meyer Cancer Center, Department of Urology, Weill Cornell Medical College & New York-Presbyterian Hospital, New York, NY
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Mosconi L, Rahman A, Diaz I, Wu X, Scheyer O, Hristov HW, Vallabhajosula S, Isaacson RS, de Leon MJ, Brinton RD. Increased Alzheimer's risk during the menopause transition: A 3-year longitudinal brain imaging study. PLoS One 2018; 13:e0207885. [PMID: 30540774 PMCID: PMC6291073 DOI: 10.1371/journal.pone.0207885] [Citation(s) in RCA: 109] [Impact Index Per Article: 18.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2018] [Accepted: 11/07/2018] [Indexed: 01/17/2023] Open
Abstract
Two thirds of all persons with late-onset Alzheimer's disease (AD) are women. Identification of sex-based molecular mechanisms underpinning the female-based prevalence of AD would advance development of therapeutic targets during the prodromal AD phase when prevention or delay in progression is most likely to be effective. This 3-year brain imaging study examines the impact of the menopausal transition on Alzheimer's disease (AD) biomarker changes [brain β-amyloid load via 11C-PiB PET, and neurodegeneration via 18F-FDG PET and structural MRI] and cognitive performance in midlife. Fifty-nine 40-60 year-old cognitively normal participants with clinical, neuropsychological, and brain imaging exams at least 2 years apart were examined. These included 41 women [15 premenopausal controls (PRE), 14 perimenopausal (PERI), and 12 postmenopausal women (MENO)] and 18 men. We used targeted minimum loss-based estimation to evaluate AD biomarker and cognitive changes. Older age was associated with baseline Aβ and neurodegeneration markers, but not with rates of change in these biomarkers. APOE4 status influenced change in Aβ load, but not neurodegenerative changes. Longitudinally, MENO and PERI groups showed declines in estrogen-dependent memory tests as compared to men (p < .04). Adjusting for age, APOE4 status, and vascular risk confounds, the MENO and PERI groups exhibited higher rates of CMRglc decline as compared to males (p ≤ .015). The MENO group exhibited the highest rate of hippocampal volume loss (p's ≤ .001), and higher rates of Aβ deposition than males (p < .01). CMRglc decline exceeded Aβ and atrophy changes in all female groups vs. men. These findings indicate emergence and progression of a female-specific hypometabolic AD-endophenotype during the menopausal transition. These findings suggest that the optimal window of opportunity for therapeutic intervention to prevent or delay progression of AD endophenotype in women is early in the endocrine aging process.
Collapse
Affiliation(s)
- Lisa Mosconi
- Department of Neurology, Weill Cornell Medical College, New York, NY, United States of America
- Department of Psychiatry, New York University School of Medicine, New York, NY, United States of America
| | - Aneela Rahman
- Department of Neurology, Weill Cornell Medical College, New York, NY, United States of America
| | - Ivan Diaz
- Division of Biostatistics and Epidemiology, Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, NY, United States of America
| | - Xian Wu
- Division of Biostatistics and Epidemiology, Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, NY, United States of America
| | - Olivia Scheyer
- Department of Neurology, Weill Cornell Medical College, New York, NY, United States of America
| | - Hollie Webb Hristov
- Department of Neurology, Weill Cornell Medical College, New York, NY, United States of America
| | - Shankar Vallabhajosula
- Department of Radiology, Weill Cornell Medical College, New York NY, United States of America
| | - Richard S. Isaacson
- Department of Neurology, Weill Cornell Medical College, New York, NY, United States of America
| | - Mony J. de Leon
- Department of Psychiatry, New York University School of Medicine, New York, NY, United States of America
| | - Roberta Diaz Brinton
- Departments of Pharmacology and Neurology, College of Medicine, University of Arizona, Tucson, United States of America
| |
Collapse
|
23
|
Raffalt PC, Vallabhajosula S, Renz JJ, Mukherjee M, Stergiou N. Lower limb joint angle variability and dimensionality are different in stairmill climbing and treadmill walking. R Soc Open Sci 2018; 5:180996. [PMID: 30662723 PMCID: PMC6304153 DOI: 10.1098/rsos.180996] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/20/2018] [Accepted: 10/18/2018] [Indexed: 06/09/2023]
Abstract
The present study tested if the quadratic relationship which exists between stepping frequency and gait dynamics in walking can be generalized to stairmill climbing. To accomplish this, we investigated the joint angle dynamics and variability during continuous stairmill climbing at stepping frequencies both above and below the preferred stepping frequency (PSF). Nine subjects performed stairmill climbing at 80, 90, 100, 110 and 120% PSF and treadmill walking at preferred walking speed during which sagittal hip, knee and ankle angles were extracted. Joint angle dynamics were quantified by the largest Lyapunov exponent (LyE) and correlation dimension (CoD). Joint angle variability was estimated by the mean ensemble standard deviation (meanSD). MeanSD and CoD for all joints were significantly higher during stairmill climbing but there were no task differences in LyE. Changes in stepping frequency had only limited effect on joint angle variability and did not affect joint angle dynamics. Thus, we concluded that the quadratic relationship between stepping frequency and gait dynamics observed in walking is not present in stairmill climbing based on the investigated parameters.
Collapse
Affiliation(s)
- P. C. Raffalt
- Julius Wolff Institute for Biomechanics and Musculoskeletal Regeneration, Charité – Universitätsmedizin Berlin, Berlin, Germany
- Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - S. Vallabhajosula
- Department of Physical Therapy Education, School of Health Sciences, Elon University, Elon, NC, USA
| | - J. J. Renz
- Department of Biomechanics, College of Education, University of Nebraska Medical Center, Omaha, NE, USA
| | - M. Mukherjee
- Department of Biomechanics, College of Education, University of Nebraska Medical Center, Omaha, NE, USA
| | - N. Stergiou
- Department of Biomechanics, College of Education, University of Nebraska Medical Center, Omaha, NE, USA
- Department of Environmental Agricultural and Occupational Health, College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA
| |
Collapse
|
24
|
Walters MJ, Sterling J, Quinn C, Ganzer C, Osorio RS, Andrews RD, Matthews DC, Vallabhajosula S, de Leon MJ, Isaacson RS, Mosconi L. Associations of lifestyle and vascular risk factors with Alzheimer's brain biomarker changes during middle age: a 3-year longitudinal study in the broader New York City area. BMJ Open 2018; 8:e023664. [PMID: 30478117 PMCID: PMC6254410 DOI: 10.1136/bmjopen-2018-023664] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
OBJECTIVE To investigate the associations between lifestyle and vascular risk factors and changes in Alzheimer's disease (AD) biomarkers (beta-amyloid load via 11C-PiB PET, glucose metabolism via 18F-FDG PET and neurodegeneration via structural MRI) and global cognition in middle-aged asymptomatic participants at risk for AD. DESIGN Prospective, longitudinal. SETTING The study was conducted at New York University Langone/Weill Cornell Medical Centres in New York City. PARTICIPANTS Seventy cognitively normal participants from multiple community sources, aged 30-60 years with lifestyle measures (diet, intellectual activity and physical activity), vascular risk measures and two imaging biomarkers visits over at least 2 years, were included in the study. OUTCOME MEASURES We examined MRI-based cortical thickness, fluoro-deoxy-glucose (FDG) glucose metabolism and PiB beta-amyloid in AD-vulnerable regions. A global cognitive z-score served as our summary cognition measure. We used regression change models to investigate the associations of clinical, lifestyle and vascular risk measures with changes in AD biomarkers and global cognition. RESULTS Diet influenced changes in glucose metabolism, but not amyloid or cortical thickness changes. With and without accounting for demographic measures, vascular risk and baseline FDG measures, lower adherence to a Mediterranean-style diet was associated with faster rates of FDG decline in the posterior cingulate cortex (p≤0.05) and marginally in the frontal cortex (p=0.07). None of the other lifestyle variables or vascular measures showed associations with AD biomarker changes. Higher baseline plasma homocysteine was associated with faster rates of decline in global cognition, with and without accounting for lifestyle and biomarker measures (p=0.048). None of the lifestyle variables were associated with cognition. CONCLUSIONS Diet influenced brain glucose metabolism in middle-aged participants, while plasma homocysteine explained variability in cognitive performance. These findings suggest that these modifiable risk factors affect AD risk through different pathways and support further investigation of risk reduction strategies in midlife.
Collapse
Affiliation(s)
| | - Joanna Sterling
- Department of Psychology, Woodrow Wilson School of Public and International Affairs, Princeton University, Princeton, New Jersey, USA
| | - Crystal Quinn
- Department of Psychiatry, New York University School of Medicine, New York, USA
- The Graduate Center, City University of New York, New York, USA
| | - Christine Ganzer
- Hunter-Bellevue School of Nursing, Hunter College, New York, USA
| | - Ricardo S Osorio
- Department of Psychiatry, New York University School of Medicine, New York, USA
| | | | | | | | - Mony J de Leon
- Department of Psychiatry, New York University School of Medicine, New York, USA
| | | | - Lisa Mosconi
- Department of Neurology, Weill Cornell Medical College, New York, USA
- Department of Psychiatry, New York University School of Medicine, New York, USA
- Department of Nutrition and Food Studies, New York University Steinhardt School of Culture, Education, and Human Development, New York, USA
| |
Collapse
|
25
|
Tagawa S, Vallabhajosula S, Jhanwar Y, Hackett A, Oromendia C, Naiz M, Goldsmith S, Nanus D, Beltran H, Molina A, Faltas B, Sreekumar J, Babich J, Ballman K, Bander N. Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy284.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
26
|
Corwin C, Nikolopoulou A, Pan AL, Nunez-Santos M, Vallabhajosula S, Serrano P, Babich J, Figueiredo-Pereira ME. Prostaglandin D2/J2 signaling pathway in a rat model of neuroinflammation displaying progressive parkinsonian-like pathology: potential novel therapeutic targets. J Neuroinflammation 2018; 15:272. [PMID: 30236122 PMCID: PMC6146649 DOI: 10.1186/s12974-018-1305-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2018] [Accepted: 09/04/2018] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Prostaglandins are products of the cyclooxygenase pathway, which is implicated in Parkinson's disease (PD). Limited knowledge is available on mechanisms by which prostaglandins contribute to PD neurodegeneration. To address this gap, we focused on the prostaglandin PGD2/J2 signaling pathway, because PGD2 is the most abundant prostaglandin in the brain, and the one that increases the most under pathological conditions. Moreover, PGJ2 is spontaneously derived from PGD2. METHODS In this study, we determined in rats the impact of unilateral nigral PGJ2-microinfusions on COX-2, lipocalin-type PGD2 synthase (L-PGDS), PGD2/J2 receptor 2 (DP2), and 15 hydroxyprostaglandin dehydrogenase (15-PGDH). Nigral dopaminergic (DA) and microglial distribution and expression levels of these key factors of the prostaglandin D2/J2 pathway were evaluated by immunohistochemistry. PGJ2-induced motor deficits were assessed with the cylinder test. We also determined whether oral treatment with ibuprofen improved the PD-like pathology induced by PGJ2. RESULTS PGJ2 treatment induced progressive PD-like pathology in the rats. Concomitant with DA neuronal loss in the substantia nigra pars compacta (SNpc), PGJ2-treated rats exhibited microglia and astrocyte activation and motor deficits. In DA neurons, COX-2, L-PGDS, and 15-PGDH levels increased significantly in PGJ2-treated rats compared to controls, while DP2 receptor levels were unchanged. In microglia, DP2 receptors were basically non-detectable, while COX-2 and L-PGDS levels increased upon PGJ2-treatment, and 15-PGDH remained unchanged. 15-PGDH was also detected in oligodendrocytes. Notably, ibuprofen prevented most PGJ2-induced PD-like pathology. CONCLUSIONS The PGJ2-induced rat model develops progressive PD pathology, which is a hard-to-mimic aspect of this disorder. Moreover, prevention of most PGJ2-induced PD-like pathology with ibuprofen suggests a positive feedback mechanism between PGJ2 and COX-2 that could lead to chronic neuroinflammation. Notably, this is the first study that analyzes the nigral dopaminergic and microglial distribution and levels of factors of the PGD2/J2 signaling pathway in rodents. Our findings support the notions that upregulation of COX-2 and L-PGDS may be important in the PGJ2 evoked PD-like pathology, and that neuronal DP2 receptor antagonists and L-PGDS inhibitors may be novel pharmacotherapeutics to relieve neuroinflammation-mediated neurodegeneration in PD, circumventing the adverse side effects of cyclooxygenase inhibitors.
Collapse
Affiliation(s)
- Chuhyon Corwin
- Department of Biological Sciences, Hunter College, Neuroscience Collaborative Program, Graduate Center, The City University of New York, 695 Park Ave., New York, NY, 10065, USA
| | | | - Allen L Pan
- Department of Biological Sciences, Hunter College, Neuroscience Collaborative Program, Graduate Center, The City University of New York, 695 Park Ave., New York, NY, 10065, USA
| | - Mariela Nunez-Santos
- Department of Biological Sciences, Hunter College, Neuroscience Collaborative Program, Graduate Center, The City University of New York, 695 Park Ave., New York, NY, 10065, USA
| | | | - Peter Serrano
- Department of Psychology, Hunter College, The City University of New York, New York, NY, USA
| | - John Babich
- Department of Radiology, Weill Cornell Medicine, New York, NY, USA
| | - Maria E Figueiredo-Pereira
- Department of Biological Sciences, Hunter College, Neuroscience Collaborative Program, Graduate Center, The City University of New York, 695 Park Ave., New York, NY, 10065, USA.
| |
Collapse
|
27
|
Kang Y, Henchcliffe C, Verma A, Vallabhajosula S, He B, Kothari PJ, Pryor KO, Mozley PD. 18F-FPEB PET/CT Shows mGluR5 Upregulation in Parkinson's Disease. J Neuroimaging 2018; 29:97-103. [DOI: 10.1111/jon.12563] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2018] [Revised: 09/03/2018] [Accepted: 09/04/2018] [Indexed: 11/28/2022] Open
Affiliation(s)
- Yeona Kang
- Department of Radiology; Weill Cornell Medicine; New York NY
| | | | | | | | - Bin He
- Department of Radiology; Weill Cornell Medicine; New York NY
| | | | - Kane O. Pryor
- Department of Anesthesiology; Weill Cornell Medicine; New York NY
| | - P. David Mozley
- Department of Radiology; Weill Cornell Medicine; New York NY
| |
Collapse
|
28
|
Kang Y, Mozley PD, Verma A, Schlyer D, Henchcliffe C, Gauthier SA, Chiao PC, He B, Nikolopoulou A, Logan J, Sullivan JM, Pryor KO, Hesterman J, Kothari PJ, Vallabhajosula S. Noninvasive PK11195-PET Image Analysis Techniques Can Detect Abnormal Cerebral Microglial Activation in Parkinson's Disease. J Neuroimaging 2018; 28:496-505. [PMID: 29727504 PMCID: PMC6174975 DOI: 10.1111/jon.12519] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2018] [Accepted: 04/15/2018] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND AND PURPOSE Neuroinflammation has been implicated in the pathophysiology of Parkinson's disease (PD), which might be influenced by successful neuroprotective drugs. The uptake of [11 C](R)-PK11195 (PK) is often considered to be a proxy for neuroinflammation, and can be quantified using the Logan graphical method with an image-derived blood input function, or the Logan reference tissue model using automated reference region extraction. The purposes of this study were (1) to assess whether these noninvasive image analysis methods can discriminate between patients with PD and healthy volunteers (HVs), and (2) to establish the effect size that would be required to distinguish true drug-induced changes from system variance in longitudinal trials. METHODS The sample consisted of 20 participants with PD and 19 HVs. Two independent teams analyzed the data to compare the volume of distribution calculated using image-derived input functions (IDIFs), and binding potentials calculated using the Logan reference region model. RESULTS With all methods, the higher signal-to-background in patients resulted in lower variability and better repeatability than in controls. We were able to use noninvasive techniques showing significantly increased uptake of PK in multiple brain regions of participants with PD compared to HVs. CONCLUSION Although not necessarily reflecting absolute values, these noninvasive image analysis methods can discriminate between PD patients and HVs. We see a difference of 24% in the substantia nigra between PD and HV with a repeatability coefficient of 13%, showing that it will be possible to estimate responses in longitudinal, within subject trials of novel neuroprotective drugs.
Collapse
Affiliation(s)
| | | | | | - David Schlyer
- Weill Cornell MedicineNew YorkNY
- Brookhaven National LaboratoriesNY
| | | | | | | | - Bin He
- Weill Cornell MedicineNew YorkNY
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Berti V, Walters M, Sterling J, Quinn CG, Logue M, Andrews R, Matthews DC, Osorio RS, Pupi A, Vallabhajosula S, Isaacson RS, de Leon MJ, Mosconi L. Mediterranean diet and 3-year Alzheimer brain biomarker changes in middle-aged adults. Neurology 2018; 90:e1789-e1798. [PMID: 29653991 DOI: 10.1212/wnl.0000000000005527] [Citation(s) in RCA: 104] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2017] [Accepted: 02/26/2018] [Indexed: 01/29/2023] Open
Abstract
OBJECTIVE To examine in a 3-year brain imaging study the effects of higher vs lower adherence to a Mediterranean-style diet (MeDi) on Alzheimer disease (AD) biomarker changes (brain β-amyloid load via 11C-Pittsburgh compound B [PiB] PET and neurodegeneration via 18F-fluorodeoxyglucose [FDG] PET and structural MRI) in midlife. METHODS Seventy 30- to 60-year-old cognitively normal participants with clinical, neuropsychological, and dietary examinations and imaging biomarkers at least 2 years apart were examined. These included 34 participants with higher (MeDi+) and 36 with lower (MeDi-) MeDi adherence. Statistical parametric mapping and volumes of interest were used to compare AD biomarkers between groups at cross section and longitudinally. RESULTS MeDi groups were comparable for clinical and neuropsychological measures. At baseline, compared to the MeDi+ group, the MeDi- group showed reduced FDG-PET glucose metabolism (CMRglc) and higher PiB-PET deposition in AD-affected regions (p < 0.001). Longitudinally, the MeDi--group showed CMRglc declines and PiB increases in these regions, which were greater than those in the MeDi+ group (pinteraction < 0.001). No effects were observed on MRI. Higher MeDi adherence was estimated to provide 1.5 to 3.5 years of protection against AD. CONCLUSION Lower MeDi adherence was associated with progressive AD biomarker abnormalities in middle-aged adults. These data support further investigation of dietary interventions for protection against brain aging and AD.
Collapse
Affiliation(s)
- Valentina Berti
- From the Department of Clinical Pathophysiology (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Department of Nutrition and Food Studies (M.W., L.M.), New York University Steinhardt School of Culture, Education, and Human Development, NY; Woodrow Wilson School of Public and International Affairs (J.S.), Department of Psychology, Princeton University, NJ; Department of Psychiatry (C.G.Q., M.L., R.S.O., L.M.), New York University School of Medicine, NY; ADM Diagnostics (R.A., D.C.M., M.J.d.L.), Chicago, IL; and Departments of Radiology (S.V.) and Neurology (R.S.I., L.M.), Weill Cornell Medical Center/NewYork-Presbyterian, NY
| | - Michelle Walters
- From the Department of Clinical Pathophysiology (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Department of Nutrition and Food Studies (M.W., L.M.), New York University Steinhardt School of Culture, Education, and Human Development, NY; Woodrow Wilson School of Public and International Affairs (J.S.), Department of Psychology, Princeton University, NJ; Department of Psychiatry (C.G.Q., M.L., R.S.O., L.M.), New York University School of Medicine, NY; ADM Diagnostics (R.A., D.C.M., M.J.d.L.), Chicago, IL; and Departments of Radiology (S.V.) and Neurology (R.S.I., L.M.), Weill Cornell Medical Center/NewYork-Presbyterian, NY
| | - Joanna Sterling
- From the Department of Clinical Pathophysiology (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Department of Nutrition and Food Studies (M.W., L.M.), New York University Steinhardt School of Culture, Education, and Human Development, NY; Woodrow Wilson School of Public and International Affairs (J.S.), Department of Psychology, Princeton University, NJ; Department of Psychiatry (C.G.Q., M.L., R.S.O., L.M.), New York University School of Medicine, NY; ADM Diagnostics (R.A., D.C.M., M.J.d.L.), Chicago, IL; and Departments of Radiology (S.V.) and Neurology (R.S.I., L.M.), Weill Cornell Medical Center/NewYork-Presbyterian, NY
| | - Crystal G Quinn
- From the Department of Clinical Pathophysiology (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Department of Nutrition and Food Studies (M.W., L.M.), New York University Steinhardt School of Culture, Education, and Human Development, NY; Woodrow Wilson School of Public and International Affairs (J.S.), Department of Psychology, Princeton University, NJ; Department of Psychiatry (C.G.Q., M.L., R.S.O., L.M.), New York University School of Medicine, NY; ADM Diagnostics (R.A., D.C.M., M.J.d.L.), Chicago, IL; and Departments of Radiology (S.V.) and Neurology (R.S.I., L.M.), Weill Cornell Medical Center/NewYork-Presbyterian, NY
| | - Michelle Logue
- From the Department of Clinical Pathophysiology (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Department of Nutrition and Food Studies (M.W., L.M.), New York University Steinhardt School of Culture, Education, and Human Development, NY; Woodrow Wilson School of Public and International Affairs (J.S.), Department of Psychology, Princeton University, NJ; Department of Psychiatry (C.G.Q., M.L., R.S.O., L.M.), New York University School of Medicine, NY; ADM Diagnostics (R.A., D.C.M., M.J.d.L.), Chicago, IL; and Departments of Radiology (S.V.) and Neurology (R.S.I., L.M.), Weill Cornell Medical Center/NewYork-Presbyterian, NY
| | - Randolph Andrews
- From the Department of Clinical Pathophysiology (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Department of Nutrition and Food Studies (M.W., L.M.), New York University Steinhardt School of Culture, Education, and Human Development, NY; Woodrow Wilson School of Public and International Affairs (J.S.), Department of Psychology, Princeton University, NJ; Department of Psychiatry (C.G.Q., M.L., R.S.O., L.M.), New York University School of Medicine, NY; ADM Diagnostics (R.A., D.C.M., M.J.d.L.), Chicago, IL; and Departments of Radiology (S.V.) and Neurology (R.S.I., L.M.), Weill Cornell Medical Center/NewYork-Presbyterian, NY
| | - Dawn C Matthews
- From the Department of Clinical Pathophysiology (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Department of Nutrition and Food Studies (M.W., L.M.), New York University Steinhardt School of Culture, Education, and Human Development, NY; Woodrow Wilson School of Public and International Affairs (J.S.), Department of Psychology, Princeton University, NJ; Department of Psychiatry (C.G.Q., M.L., R.S.O., L.M.), New York University School of Medicine, NY; ADM Diagnostics (R.A., D.C.M., M.J.d.L.), Chicago, IL; and Departments of Radiology (S.V.) and Neurology (R.S.I., L.M.), Weill Cornell Medical Center/NewYork-Presbyterian, NY
| | - Ricardo S Osorio
- From the Department of Clinical Pathophysiology (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Department of Nutrition and Food Studies (M.W., L.M.), New York University Steinhardt School of Culture, Education, and Human Development, NY; Woodrow Wilson School of Public and International Affairs (J.S.), Department of Psychology, Princeton University, NJ; Department of Psychiatry (C.G.Q., M.L., R.S.O., L.M.), New York University School of Medicine, NY; ADM Diagnostics (R.A., D.C.M., M.J.d.L.), Chicago, IL; and Departments of Radiology (S.V.) and Neurology (R.S.I., L.M.), Weill Cornell Medical Center/NewYork-Presbyterian, NY
| | - Alberto Pupi
- From the Department of Clinical Pathophysiology (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Department of Nutrition and Food Studies (M.W., L.M.), New York University Steinhardt School of Culture, Education, and Human Development, NY; Woodrow Wilson School of Public and International Affairs (J.S.), Department of Psychology, Princeton University, NJ; Department of Psychiatry (C.G.Q., M.L., R.S.O., L.M.), New York University School of Medicine, NY; ADM Diagnostics (R.A., D.C.M., M.J.d.L.), Chicago, IL; and Departments of Radiology (S.V.) and Neurology (R.S.I., L.M.), Weill Cornell Medical Center/NewYork-Presbyterian, NY
| | - Shankar Vallabhajosula
- From the Department of Clinical Pathophysiology (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Department of Nutrition and Food Studies (M.W., L.M.), New York University Steinhardt School of Culture, Education, and Human Development, NY; Woodrow Wilson School of Public and International Affairs (J.S.), Department of Psychology, Princeton University, NJ; Department of Psychiatry (C.G.Q., M.L., R.S.O., L.M.), New York University School of Medicine, NY; ADM Diagnostics (R.A., D.C.M., M.J.d.L.), Chicago, IL; and Departments of Radiology (S.V.) and Neurology (R.S.I., L.M.), Weill Cornell Medical Center/NewYork-Presbyterian, NY
| | - Richard S Isaacson
- From the Department of Clinical Pathophysiology (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Department of Nutrition and Food Studies (M.W., L.M.), New York University Steinhardt School of Culture, Education, and Human Development, NY; Woodrow Wilson School of Public and International Affairs (J.S.), Department of Psychology, Princeton University, NJ; Department of Psychiatry (C.G.Q., M.L., R.S.O., L.M.), New York University School of Medicine, NY; ADM Diagnostics (R.A., D.C.M., M.J.d.L.), Chicago, IL; and Departments of Radiology (S.V.) and Neurology (R.S.I., L.M.), Weill Cornell Medical Center/NewYork-Presbyterian, NY
| | - Mony J de Leon
- From the Department of Clinical Pathophysiology (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Department of Nutrition and Food Studies (M.W., L.M.), New York University Steinhardt School of Culture, Education, and Human Development, NY; Woodrow Wilson School of Public and International Affairs (J.S.), Department of Psychology, Princeton University, NJ; Department of Psychiatry (C.G.Q., M.L., R.S.O., L.M.), New York University School of Medicine, NY; ADM Diagnostics (R.A., D.C.M., M.J.d.L.), Chicago, IL; and Departments of Radiology (S.V.) and Neurology (R.S.I., L.M.), Weill Cornell Medical Center/NewYork-Presbyterian, NY
| | - Lisa Mosconi
- From the Department of Clinical Pathophysiology (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Department of Nutrition and Food Studies (M.W., L.M.), New York University Steinhardt School of Culture, Education, and Human Development, NY; Woodrow Wilson School of Public and International Affairs (J.S.), Department of Psychology, Princeton University, NJ; Department of Psychiatry (C.G.Q., M.L., R.S.O., L.M.), New York University School of Medicine, NY; ADM Diagnostics (R.A., D.C.M., M.J.d.L.), Chicago, IL; and Departments of Radiology (S.V.) and Neurology (R.S.I., L.M.), Weill Cornell Medical Center/NewYork-Presbyterian, NY.
| |
Collapse
|
30
|
Tagawa ST, Vallabhajosula S, Jhanwar Y, Ballman KV, Hackett A, Emmerich L, Babich J, Sartor AO, Harshman LC, Beltran H, Molina AM, Nanus DM, Bander NH. Phase I dose-escalation study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.6_suppl.tps399] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
TPS399 Background: PC is a radiosensitive disease. PSMA is overexpressed in advanced PC with upregulation by androgen receptor (AR) pathway dysregulation; limited expression exists in other organs. A series of sequential studies of beta-emitting radiolabeled anti-PSMA monoclonal antibody (mAb) J591 have demonstrated accurate targeting, efficacy with dose-response effect, and safety with predictable, reversible dose-limiting myelosuppression. Alpha emitters are significantly more potent with a shorter range than beta emitters. Though there is no direct tumor-targeting, the bone-targeting alpha emitter Ra223 is approved. Anecdotal reports of PSMA small molecule targeted alpha emitters have hinted at efficacy but are limited by xerostomia and in mouse models may lead to long-term renal damage. Intact mAb J591 has comparatively no to minimal distribution in salivary glands and kidneys. Preclinical studies demonstrated purity, immunoreactivity, and stability with efficacy in a xenograft model [AACR 2017]. Methods: Men with progressive mCRPC following at least 1 potent AR-targeted agent (e.g. abi/enza) and docetaxel (or unfit/refuse chemo) without limit of # prior therapies (excluding beta-emitting bone-targeted radioisotopes) provided adequate organ function will undergo imaging with 68Ga-PSMA-11 PET/CT followed by a single dose of 225Ac-J591. Single-subject cohorts will be enrolled until grade > 1 attributable toxicity, then transition to 3+3 design. Cohort 1 = 13.3 KBq/kg with planned escalation up to 93.3 KBq/kg of 225Ac with fixed 20 mg J591. Dose-limiting toxicity (DLT) is defined as attributable grade 4 heme toxicity or grade 3/4 non-heme toxicity. Planned cohort expansion will occur at recommended phase 2 dose (RP2D) in a 2-stage design. The primary endpoint is determination of DLT and RP2D. Secondary endpoints include toxicity, PSA decline rate, RECIST response, PFS, rPFS, OS, and patient reported outcomes (FACT-P and BPI-SF). Correlatives include baseline/follow up PSMA imaging, CTC count (CellSearch) changes, tissue and circulating genomic assessment, and immune studies. Enrollment began in October, 2017. Clinical trial information: NCT03276572.
Collapse
|
31
|
Zanderigo F, Kang Y, Kumar D, Nikolopoulou A, Mozley PD, Kothari PJ, He B, Schlyer D, Rapoport SI, Oquendo MA, Vallabhajosula S, Mann JJ, Sublette ME. [ 11 C]arachidonic acid incorporation measurement in human brain: Optimization for clinical use. Synapse 2017; 72. [PMID: 29144569 DOI: 10.1002/syn.22018] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2017] [Revised: 11/10/2017] [Accepted: 11/12/2017] [Indexed: 01/06/2023]
Abstract
Arachidonic acid (AA) is involved in signal transduction, neuroinflammation, and production of eicosanoid metabolites. The AA brain incorporation coefficient (K*) is quantifiable in vivo using [11 C]AA positron emission tomography, although repeatability remains undetermined. We evaluated K* estimates obtained with population-based metabolite correction (PBMC) and image-derived input function (IDIF) in comparison to arterial blood-based estimates, and compared repeatability. Eleven healthy volunteers underwent a [11 C]AA scan; five repeated the scan 6 weeks later, simulating a pre- and post-treatment study design. For all scans, arterial blood was sampled to measure [11 C]AA plasma radioactivity. Plasma [11 C]AA parent fraction was measured in 5 scans. K* was quantified using both blood data and IDIF, corrected for [11 C]AA parent fraction using both PBMC (from published values) and individually measured values (when available). K* repeatability was calculated in the test-retest subset. K* estimates based on blood and individual metabolites were highly correlated with estimates using PBMC with arterial input function (r = 0.943) or IDIF (r = 0.918) in the subset with measured metabolites. In the total dataset, using PBMC, IDIF-based estimates were moderately correlated with arterial input function-based estimates (r = 0.712). PBMC and IDIF-based K* estimates were ∼6.4% to ∼11.9% higher, on average, than blood-based estimates. Average K* test-retest absolute percent difference values obtained using blood data or IDIF, assuming PBMC for both, were between 6.7% and 13.9%, comparable to other radiotracers. Our results support the possibility of simplified [11 C]AA data acquisition through eliminating arterial blood sampling and metabolite analysis, while retaining comparable repeatability and validity.
Collapse
Affiliation(s)
- Francesca Zanderigo
- Molecular Imaging and Neuropathology Division, New York State Psychiatric Institute, New York, New York.,Department of Psychiatry, Columbia University, New York, New York
| | - Yeona Kang
- Department of Radiology, Weill Cornell Medicine, New York, New York
| | - Dileep Kumar
- Molecular Imaging and Neuropathology Division, New York State Psychiatric Institute, New York, New York
| | | | - P David Mozley
- Department of Radiology, Weill Cornell Medicine, New York, New York
| | - Paresh J Kothari
- Department of Radiology, Weill Cornell Medicine, New York, New York
| | - Bin He
- Department of Radiology, Weill Cornell Medicine, New York, New York
| | - David Schlyer
- Department of Radiology, Weill Cornell Medicine, New York, New York
| | | | - Maria A Oquendo
- Molecular Imaging and Neuropathology Division, New York State Psychiatric Institute, New York, New York.,Department of Psychiatry, Columbia University, New York, New York
| | | | - J John Mann
- Molecular Imaging and Neuropathology Division, New York State Psychiatric Institute, New York, New York.,Department of Psychiatry, Columbia University, New York, New York.,Department of Radiology, Columbia University, New York, New York
| | - M Elizabeth Sublette
- Molecular Imaging and Neuropathology Division, New York State Psychiatric Institute, New York, New York.,Department of Psychiatry, Columbia University, New York, New York
| |
Collapse
|
32
|
Mosconi L, Berti V, Quinn C, McHugh P, Petrongolo G, Osorio RS, Connaughty C, Pupi A, Vallabhajosula S, Isaacson RS, de Leon MJ, Swerdlow RH, Brinton RD. Perimenopause and emergence of an Alzheimer's bioenergetic phenotype in brain and periphery. PLoS One 2017; 12:e0185926. [PMID: 29016679 PMCID: PMC5634623 DOI: 10.1371/journal.pone.0185926] [Citation(s) in RCA: 85] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2017] [Accepted: 09/21/2017] [Indexed: 01/07/2023] Open
Abstract
After advanced age, female sex is the major risk factor for Alzheimer’s disease (AD). The biological mechanisms underlying the increased AD risk in women remain largely undetermined. Preclinical studies identified the perimenopause to menopause transition, a neuroendocrine transition state unique to the female, as a sex-specific risk factor for AD. In animals, estrogenic regulation of cerebral glucose metabolism (CMRglc) falters during perimenopause. This is evident in glucose hypometabolism and decline in mitochondrial efficiency which is sustained thereafter. This study bridges basic to clinical science to characterize brain bioenergetics in a cohort of forty-three, 40–60 year-old clinically and cognitively normal women at different endocrine transition stages including premenopause (controls, CNT, n = 15), perimenopause (PERI, n = 14) and postmenopause (MENO, n = 14). All participants received clinical, laboratory and neuropsychological examinations, 18F-fluoro-deoxyglucose (FDG)-Positron Emission Tomography (PET) FDG-PET scans to estimate CMRglc, and platelet mitochondrial cytochrome oxidase (COX) activity measures. Statistical parametric mapping and multiple regression models were used to examine clinical, CMRglc and COX data across groups. As expected, the MENO group was older than PERI and controls. Groups were otherwise comparable for clinical measures and distribution of APOE4 genotype. Both MENO and PERI groups exhibited reduced CMRglc in AD-vulnerable regions which was correlated with decline in mitochondrial COX activity compared to CNT (p’s<0.001). A gradient in biomarker abnormalities was most pronounced in MENO, intermediate in PERI, and lowest in CNT (p<0.001). Biomarkers correlated with immediate and delayed memory scores (Pearson’s 0.26≤r≤0.32, p≤0.05). These findings validate earlier preclinical findings and indicate emergence of bioenergetic deficits in perimenopausal and postmenopausal women, suggesting that the optimal window of opportunity for therapeutic intervention in women is early in the endocrine aging process.
Collapse
Affiliation(s)
- Lisa Mosconi
- Department of Neurology, Weill Cornell Medical College, New York, NY, United States of America.,Department of Psychiatry, New York University School of Medicine, New York, NY, United States of America
| | - Valentina Berti
- Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Florence, Italy
| | - Crystal Quinn
- Department of Psychiatry, New York University School of Medicine, New York, NY, United States of America
| | - Pauline McHugh
- Department of Psychiatry, New York University School of Medicine, New York, NY, United States of America
| | - Gabriella Petrongolo
- Department of Psychiatry, New York University School of Medicine, New York, NY, United States of America
| | - Ricardo S Osorio
- Department of Psychiatry, New York University School of Medicine, New York, NY, United States of America
| | - Christopher Connaughty
- Department of Psychiatry, New York University School of Medicine, New York, NY, United States of America
| | - Alberto Pupi
- Department of Clinical Pathophysiology, Nuclear Medicine Unit, University of Florence, Florence, Italy
| | - Shankar Vallabhajosula
- Department of Radiology, Weill Cornell Medical College, New York, NY, United States of America
| | - Richard S Isaacson
- Department of Neurology, Weill Cornell Medical College, New York, NY, United States of America
| | - Mony J de Leon
- Department of Psychiatry, New York University School of Medicine, New York, NY, United States of America
| | - Russell H Swerdlow
- Department of Neurology, University of Kansas School of Medicine, Kansas City, United States of America
| | - Roberta Diaz Brinton
- Departments of Pharmacology and Neurology, University of Arizona College of Medicine, Tucson, AZ, United States of America
| |
Collapse
|
33
|
Kelly JM, Amor-Coarasa A, Nikolopoulou A, Kim D, Williams C, Vallabhajosula S, Babich JW. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of 68Ga 3+, 111In 3+, 177Lu 3+ and 225Ac 3. Nucl Med Biol 2017; 55:38-46. [PMID: 29055836 DOI: 10.1016/j.nucmedbio.2017.10.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2017] [Revised: 09/21/2017] [Accepted: 10/01/2017] [Indexed: 01/12/2023]
Abstract
INTRODUCTION Recent successes in the treatment of metastatic castration-resistant prostate cancer (mCRPCa) by systemic endoradiotherapy has sparked renewed interest in developing small molecule ligands targeting prostate-specific membrane antigen (PSMA) and chelators capable of stable complexation of metal radionuclides for imaging and therapy. As the size and coordination number of metals for imaging, such as 68Ga3+, and for targeted therapy, such as 177Lu3+ and 225Ac3+, are substantially different, they may show a preference for macrocycles of different denticity. We have prepared three simple conjugates that target PSMA and form radiometal complexes through coordination by either octa-, deca-, or dodecadentate tetraazacyclododecane chelators. The complex formation and metal ion selectivity of these constructs were determined at two relevant temperatures, complex stability was examined in vitro, and tumor targeting was demonstrated in preclinical PCa models with a view towards identifying a candidate with potential value as a theranostic agent for the imaging and therapy of mCRPCa. METHODS Three bifunctional chelates with high denticity, including the octadentate chelate DOTA, the decadentate 3p-C-DEPA and a novel dodecadentate analogue of DEPA, were synthesized and conjugated to a glutamate-urea-lysine (EuK) pharmacophore (EuK-DOTA, EuK-107 and EuK-106, respectively) to enable targeting of PSMA. The metal ion selectivity for each construct was determined by incubation at 25 °C and 95 °C with the trivalent radiometals 68Ga3+, 111In3+, 177Lu3+ and 225Ac3+. PSMA binding affinity was determined by competitive binding using LNCaP cells, while in vivo tumor targeting of the 68Ga-labeled constructs was examined by positron emission tomography (PET) in LNCaP xenograft tumor-bearing mice. RESULTS PMSA affinities (IC50 values) were 13.3 ± 0.9 nM for EuK-DOTA, 18.0 ± 3.7 nM for EuK-107 and 42.6 ± 6.6 nM for EuK-106. EuK-107 and EuK-DOTA proved to rapidly and near quantitatively complex 68Ga3+, 111In3+, 177Lu3+ and 225Ac3+ at 95 °C, with EuK-107 also rapidly complexing 111In3+ and 177Lu3+ at 25 °C. The inability of EuK-106 to chelate 177Lu3+ and 225Ac3+ suggests that size of the cavity of the macrocylic ring may be more critical than the number of donor groups for the chelation of larger radiometals. In vivo, 68Ga-EuK-107 proved to have similar uptake to 68Ga-DKFZ-PSMA-617, a theranostic ligand currently in clinical evaluation, in a PSMA positive xenograft tumor model. CONCLUSIONS The broad metal ion selectivity, good in vitro affinity for PSMA and good in vivo tumor targeting suggest that EuK-107, with the 3p-C-DEPA chelator, merits further evaluation as a theranostics construct in prostate cancer.
Collapse
Affiliation(s)
- James M Kelly
- Division of Radiopharmaceutical Sciences and MI(3), Department of Radiology, Weill Cornell Medicine, New York, NY, USA
| | - Alejandro Amor-Coarasa
- Division of Radiopharmaceutical Sciences and MI(3), Department of Radiology, Weill Cornell Medicine, New York, NY, USA
| | - Anastasia Nikolopoulou
- Division of Radiopharmaceutical Sciences and MI(3), Department of Radiology, Weill Cornell Medicine, New York, NY, USA; Citigroup Biomedical Imaging Center, Weill Cornell Medicine, New York, NY, USA
| | - Dohyun Kim
- Citigroup Biomedical Imaging Center, Weill Cornell Medicine, New York, NY, USA
| | - Clarence Williams
- Division of Radiopharmaceutical Sciences and MI(3), Department of Radiology, Weill Cornell Medicine, New York, NY, USA
| | - Shankar Vallabhajosula
- Citigroup Biomedical Imaging Center, Weill Cornell Medicine, New York, NY, USA; Division of Radiochemistry in Radiology, Weill Cornell Medicine, NY, New York, USA
| | - John W Babich
- Division of Radiopharmaceutical Sciences and MI(3), Department of Radiology, Weill Cornell Medicine, New York, NY, USA; Citigroup Biomedical Imaging Center, Weill Cornell Medicine, New York, NY, USA; Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
| |
Collapse
|
34
|
Amor-Coarasa A, Kelly JM, Gruca M, Nikolopoulou A, Vallabhajosula S, Babich JW. Continuation of comprehensive quality control of the itG 68 Ge/ 68 Ga generator and production of 68 Ga-DOTATOC and 68 Ga-PSMA-HBED-CC for clinical research studies. Nucl Med Biol 2017; 53:37-39. [DOI: 10.1016/j.nucmedbio.2017.07.006] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2017] [Revised: 05/15/2017] [Accepted: 07/11/2017] [Indexed: 11/25/2022]
|
35
|
Mosconi L, Berti V, Quinn C, McHugh P, Petrongolo G, Varsavsky I, Osorio RS, Pupi A, Vallabhajosula S, Isaacson RS, de Leon MJ, Brinton RD. Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging. Neurology 2017; 89:1382-1390. [PMID: 28855400 DOI: 10.1212/wnl.0000000000004425] [Citation(s) in RCA: 158] [Impact Index Per Article: 22.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2017] [Accepted: 07/05/2017] [Indexed: 12/11/2022] Open
Abstract
OBJECTIVE This observational multimodality brain imaging study investigates emergence of endophenotypes of late-onset Alzheimer disease (AD) risk during endocrine transition states in a cohort of clinically and cognitively normal women and age-matched men. METHODS Forty-two 40- to 60-year-old cognitively normal women (15 asymptomatic perimenopausal by age [CNT], 13 perimenopausal [PERI], and 14 postmenopausal [MENO]) and 18 age- and education-matched men were examined. All patients had volumetric MRI, 18F-fluoro-2-deoxyglucose (FDG)-PET (glucose metabolism), and Pittsburgh compound B-PET scans (β-amyloid [Aβ] deposition, a hallmark of AD pathology). RESULTS As expected, the MENO group was older than the PERI and CNT groups. Otherwise, groups were comparable on clinical and neuropsychological measures and APOE4 distribution. Compared to CNT women and to men, and controlling for age, PERI and MENO groups exhibited increased indicators of AD endophenotype, including hypometabolism, increased Aβ deposition, and reduced gray and white matter volumes in AD-vulnerable regions (p < 0.001). AD biomarker abnormalities were greatest in MENO, intermediate in PERI, and lowest in CNT women (p < 0.001). Aβ deposition was exacerbated in APOE4-positive MENO women relative to the other groups (p < 0.001). CONCLUSIONS Multimodality brain imaging indicates sex differences in development of the AD endophenotype, suggesting that the preclinical AD phase is early in the female aging process and coincides with the endocrine transition of perimenopause. These data indicate that the optimal window of opportunity for therapeutic intervention in women is early in the endocrine aging process.
Collapse
Affiliation(s)
- Lisa Mosconi
- From the Departments of Neurology (L.M., R.S.I.) and Radiology (S.V.), Weill Cornell Medical College; Department of Psychiatry (L.M., C.Q., P.M., G.P., I.V., R.S.O., M.J.d.L.), New York University School of Medicine, New York; Department of Biomedical, Experimental and Clinical Sciences "Mario Serio" (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Departments of Pharmacology and Neurology (R.D.B.), College of Medicine, University of Arizona, Tucson; and Departments of Pharmacology, Biomedical Engineering, and Neurology (R.D.B.), University of South California, Los Angeles.
| | - Valentina Berti
- From the Departments of Neurology (L.M., R.S.I.) and Radiology (S.V.), Weill Cornell Medical College; Department of Psychiatry (L.M., C.Q., P.M., G.P., I.V., R.S.O., M.J.d.L.), New York University School of Medicine, New York; Department of Biomedical, Experimental and Clinical Sciences "Mario Serio" (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Departments of Pharmacology and Neurology (R.D.B.), College of Medicine, University of Arizona, Tucson; and Departments of Pharmacology, Biomedical Engineering, and Neurology (R.D.B.), University of South California, Los Angeles
| | - Crystal Quinn
- From the Departments of Neurology (L.M., R.S.I.) and Radiology (S.V.), Weill Cornell Medical College; Department of Psychiatry (L.M., C.Q., P.M., G.P., I.V., R.S.O., M.J.d.L.), New York University School of Medicine, New York; Department of Biomedical, Experimental and Clinical Sciences "Mario Serio" (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Departments of Pharmacology and Neurology (R.D.B.), College of Medicine, University of Arizona, Tucson; and Departments of Pharmacology, Biomedical Engineering, and Neurology (R.D.B.), University of South California, Los Angeles
| | - Pauline McHugh
- From the Departments of Neurology (L.M., R.S.I.) and Radiology (S.V.), Weill Cornell Medical College; Department of Psychiatry (L.M., C.Q., P.M., G.P., I.V., R.S.O., M.J.d.L.), New York University School of Medicine, New York; Department of Biomedical, Experimental and Clinical Sciences "Mario Serio" (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Departments of Pharmacology and Neurology (R.D.B.), College of Medicine, University of Arizona, Tucson; and Departments of Pharmacology, Biomedical Engineering, and Neurology (R.D.B.), University of South California, Los Angeles
| | - Gabriella Petrongolo
- From the Departments of Neurology (L.M., R.S.I.) and Radiology (S.V.), Weill Cornell Medical College; Department of Psychiatry (L.M., C.Q., P.M., G.P., I.V., R.S.O., M.J.d.L.), New York University School of Medicine, New York; Department of Biomedical, Experimental and Clinical Sciences "Mario Serio" (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Departments of Pharmacology and Neurology (R.D.B.), College of Medicine, University of Arizona, Tucson; and Departments of Pharmacology, Biomedical Engineering, and Neurology (R.D.B.), University of South California, Los Angeles
| | - Isabella Varsavsky
- From the Departments of Neurology (L.M., R.S.I.) and Radiology (S.V.), Weill Cornell Medical College; Department of Psychiatry (L.M., C.Q., P.M., G.P., I.V., R.S.O., M.J.d.L.), New York University School of Medicine, New York; Department of Biomedical, Experimental and Clinical Sciences "Mario Serio" (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Departments of Pharmacology and Neurology (R.D.B.), College of Medicine, University of Arizona, Tucson; and Departments of Pharmacology, Biomedical Engineering, and Neurology (R.D.B.), University of South California, Los Angeles
| | - Ricardo S Osorio
- From the Departments of Neurology (L.M., R.S.I.) and Radiology (S.V.), Weill Cornell Medical College; Department of Psychiatry (L.M., C.Q., P.M., G.P., I.V., R.S.O., M.J.d.L.), New York University School of Medicine, New York; Department of Biomedical, Experimental and Clinical Sciences "Mario Serio" (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Departments of Pharmacology and Neurology (R.D.B.), College of Medicine, University of Arizona, Tucson; and Departments of Pharmacology, Biomedical Engineering, and Neurology (R.D.B.), University of South California, Los Angeles
| | - Alberto Pupi
- From the Departments of Neurology (L.M., R.S.I.) and Radiology (S.V.), Weill Cornell Medical College; Department of Psychiatry (L.M., C.Q., P.M., G.P., I.V., R.S.O., M.J.d.L.), New York University School of Medicine, New York; Department of Biomedical, Experimental and Clinical Sciences "Mario Serio" (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Departments of Pharmacology and Neurology (R.D.B.), College of Medicine, University of Arizona, Tucson; and Departments of Pharmacology, Biomedical Engineering, and Neurology (R.D.B.), University of South California, Los Angeles
| | - Shankar Vallabhajosula
- From the Departments of Neurology (L.M., R.S.I.) and Radiology (S.V.), Weill Cornell Medical College; Department of Psychiatry (L.M., C.Q., P.M., G.P., I.V., R.S.O., M.J.d.L.), New York University School of Medicine, New York; Department of Biomedical, Experimental and Clinical Sciences "Mario Serio" (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Departments of Pharmacology and Neurology (R.D.B.), College of Medicine, University of Arizona, Tucson; and Departments of Pharmacology, Biomedical Engineering, and Neurology (R.D.B.), University of South California, Los Angeles
| | - Richard S Isaacson
- From the Departments of Neurology (L.M., R.S.I.) and Radiology (S.V.), Weill Cornell Medical College; Department of Psychiatry (L.M., C.Q., P.M., G.P., I.V., R.S.O., M.J.d.L.), New York University School of Medicine, New York; Department of Biomedical, Experimental and Clinical Sciences "Mario Serio" (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Departments of Pharmacology and Neurology (R.D.B.), College of Medicine, University of Arizona, Tucson; and Departments of Pharmacology, Biomedical Engineering, and Neurology (R.D.B.), University of South California, Los Angeles
| | - Mony J de Leon
- From the Departments of Neurology (L.M., R.S.I.) and Radiology (S.V.), Weill Cornell Medical College; Department of Psychiatry (L.M., C.Q., P.M., G.P., I.V., R.S.O., M.J.d.L.), New York University School of Medicine, New York; Department of Biomedical, Experimental and Clinical Sciences "Mario Serio" (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Departments of Pharmacology and Neurology (R.D.B.), College of Medicine, University of Arizona, Tucson; and Departments of Pharmacology, Biomedical Engineering, and Neurology (R.D.B.), University of South California, Los Angeles
| | - Roberta Diaz Brinton
- From the Departments of Neurology (L.M., R.S.I.) and Radiology (S.V.), Weill Cornell Medical College; Department of Psychiatry (L.M., C.Q., P.M., G.P., I.V., R.S.O., M.J.d.L.), New York University School of Medicine, New York; Department of Biomedical, Experimental and Clinical Sciences "Mario Serio" (V.B., A.P.), Nuclear Medicine Unit, University of Florence, Italy; Departments of Pharmacology and Neurology (R.D.B.), College of Medicine, University of Arizona, Tucson; and Departments of Pharmacology, Biomedical Engineering, and Neurology (R.D.B.), University of South California, Los Angeles
| |
Collapse
|
36
|
Chiang GC, Mao X, Kang G, Chang E, Pandya S, Vallabhajosula S, Isaacson R, Ravdin LD, Shungu DC. Relationships among Cortical Glutathione Levels, Brain Amyloidosis, and Memory in Healthy Older Adults Investigated In Vivo with 1H-MRS and Pittsburgh Compound-B PET. AJNR Am J Neuroradiol 2017; 38:1130-1137. [PMID: 28341718 PMCID: PMC5471116 DOI: 10.3174/ajnr.a5143] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2016] [Accepted: 01/19/2017] [Indexed: 12/12/2022]
Abstract
BACKGROUND AND PURPOSE Oxidative stress has been implicated as an important pathologic mechanism in the development of Alzheimer disease. The purpose of this study was to assess whether glutathione levels, detected noninvasively with proton MR spectroscopy, are associated with brain amyloidosis and memory in a community-dwelling cohort of healthy older adults. MATERIALS AND METHODS Fifteen cognitively healthy subjects were prospectively enrolled in this study. All subjects underwent 1H-MR spectroscopy of glutathione, a positron-emission tomography scan with an amyloid tracer, and neuropsychological testing by using the Repeatable Battery for the Assessment of Neuropsychological Status. Associations among glutathione levels, brain amyloidosis, and memory were assessed by using multivariate regression models. RESULTS Lower glutathione levels were associated with greater brain amyloidosis in the temporal (P = .03) and parietal (P = .05) regions, adjusted for apolipoprotein E ε4 carrier status. There were no significant associations between glutathione levels and cognitive scores. CONCLUSIONS This study found an association between cortical glutathione levels and brain amyloidosis in healthy older adults, suggesting a potential role for 1H-MR spectroscopy measures of glutathione as a noninvasive biomarker of early Alzheimer disease pathogenesis.
Collapse
Affiliation(s)
- G C Chiang
- From the Departments of Radiology (G.C.C., X.M., G.K., E.C., S.P., S.V., D.C.S.)
| | - X Mao
- From the Departments of Radiology (G.C.C., X.M., G.K., E.C., S.P., S.V., D.C.S.)
| | - G Kang
- From the Departments of Radiology (G.C.C., X.M., G.K., E.C., S.P., S.V., D.C.S.)
| | - E Chang
- From the Departments of Radiology (G.C.C., X.M., G.K., E.C., S.P., S.V., D.C.S.)
| | - S Pandya
- From the Departments of Radiology (G.C.C., X.M., G.K., E.C., S.P., S.V., D.C.S.)
| | - S Vallabhajosula
- From the Departments of Radiology (G.C.C., X.M., G.K., E.C., S.P., S.V., D.C.S.)
| | - R Isaacson
- Neurology (R.I., L.D.R.), Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York, New York
| | - L D Ravdin
- Neurology (R.I., L.D.R.), Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York, New York
| | - D C Shungu
- From the Departments of Radiology (G.C.C., X.M., G.K., E.C., S.P., S.V., D.C.S.)
| |
Collapse
|
37
|
Tagawa ST, Vallabhajosula S, Batra J, Christos PJ, Jhanwar Y, Goldsmith SJ, Nanus DM, Beltran H, Molina AM, Faltas B, Hackett A, Sreekumar J, Babich J, Bander NH. Phase I dose-escalation study of fractionated-dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.tps5093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
TPS5093 Background: PC is a radiosensitive disease. PSMA is selectively overexpressed in advanced PC with upregulation by androgen receptor (AR) pathway dysregulation; limited expression exists in other organs. A series of sequential studies of radiolabeled anti-PSMA antibody J591 revealed 1) targeting and safety [Bander 2003]; 2) safety and prelim efficacy [Milowsky 2004, Bander 2005]; 3) efficacy and initial dose-response [Tagawa 2013]; 4) dose-fractionation allows higher doses, ability to combine with docetaxel, confirmation of dose-response (PSA and overall survival) [ASCO 2010, 2014, 2016]; 5) predictable, reversible myelosuppression is dose-limiting [Tagawa 2013]. Small molecule PSMA inhibitor ligands can be successfully radiolabeled and are widely used for imaging and treatment in Europe. 177Lu-PSMA-617 is the most commonly used, but experience is mostly anecdotal/retrospective and no formal dose-escalation studies have been performed. Methods: Men with progressive mCRPC following at least 1 potent AR-targeted agent (e.g. abi/enza) and docetaxel (or unfit/refuse chemo) without limit of # prior therapies provided adequate organ function will undergo imaging with 68Ga-PSMA-HBED-CC PET/CT followed by escalating fractionated doses of 177Lu-PSMA-617. Cohort 1 = 3.7 GBq x2 two weeks apart up to 11.1 GBq x2 in a 3+3 dose-escalation study. Dose-limiting toxicity (DLT) is defined as attributable grade 4 heme toxicity or grade 3/4 non-heme toxicity. Planned cohort expansion will occur at recommended phase 2 dose (RP2D) in a 2-stage design. The primary endpoint is determination of DLT and RP2D. Secondary endpoints include toxicity, PSA decline rate, RECIST response, PFS, rPFS, OS. Correlatives include baseline/follow up PSMA imaging, whole body distribution of 177Lu-PSMA-617, CTC count (CellSearch) changes, tissue and circulating genomic assessment of DNA repair pathways, patient reported outcomes (FACT-P and BPI-SF). Clinical trial information: NCT03042468.
Collapse
Affiliation(s)
| | | | | | - Paul J. Christos
- New York-Presbyterian Hospital, Weill Cornell Medicine, New York, NY
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Kothari P, De BP, He B, Chen A, Chiuchiolo MJ, Kim D, Nikolopoulou A, Amor-Coarasa A, Dyke JP, Voss HU, Kaminsky SM, Foley CP, Vallabhajosula S, Hu B, DiMagno SG, Sondhi D, Crystal RG, Babich JW, Ballon D. Radioiodinated Capsids Facilitate In Vivo Non-Invasive Tracking of Adeno-Associated Gene Transfer Vectors. Sci Rep 2017; 7:39594. [PMID: 28059103 PMCID: PMC5216390 DOI: 10.1038/srep39594] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2016] [Accepted: 11/24/2016] [Indexed: 01/07/2023] Open
Abstract
Viral vector mediated gene therapy has become commonplace in clinical trials for a wide range of inherited disorders. Successful gene transfer depends on a number of factors, of which tissue tropism is among the most important. To date, definitive mapping of the spatial and temporal distribution of viral vectors in vivo has generally required postmortem examination of tissue. Here we present two methods for radiolabeling adeno-associated virus (AAV), one of the most commonly used viral vectors for gene therapy trials, and demonstrate their potential usefulness in the development of surrogate markers for vector delivery during the first week after administration. Specifically, we labeled adeno-associated virus serotype 10 expressing the coding sequences for the CLN2 gene implicated in late infantile neuronal ceroid lipofuscinosis with iodine-124. Using direct (Iodogen) and indirect (modified Bolton-Hunter) methods, we observed the vector in the murine brain for up to one week using positron emission tomography. Capsid radioiodination of viral vectors enables non-invasive, whole body, in vivo evaluation of spatial and temporal vector distribution that should inform methods for efficacious gene therapy over a broad range of applications.
Collapse
Affiliation(s)
- P. Kothari
- Citigroup Biomedical Imaging Center, Department of Radiology, Weill Cornell Medical College, New York, New York, USA
| | - B. P. De
- Department of Genetic Medicine, Weill Cornell Medical College, New York, New York, USA
| | - B. He
- Citigroup Biomedical Imaging Center, Department of Radiology, Weill Cornell Medical College, New York, New York, USA
| | - A. Chen
- Department of Genetic Medicine, Weill Cornell Medical College, New York, New York, USA
| | - M. J. Chiuchiolo
- Department of Genetic Medicine, Weill Cornell Medical College, New York, New York, USA
| | - D. Kim
- Citigroup Biomedical Imaging Center, Department of Radiology, Weill Cornell Medical College, New York, New York, USA
| | - A. Nikolopoulou
- Citigroup Biomedical Imaging Center, Department of Radiology, Weill Cornell Medical College, New York, New York, USA
| | - A. Amor-Coarasa
- Citigroup Biomedical Imaging Center, Department of Radiology, Weill Cornell Medical College, New York, New York, USA
| | - J. P. Dyke
- Citigroup Biomedical Imaging Center, Department of Radiology, Weill Cornell Medical College, New York, New York, USA
| | - H. U. Voss
- Citigroup Biomedical Imaging Center, Department of Radiology, Weill Cornell Medical College, New York, New York, USA
| | - S. M. Kaminsky
- Department of Genetic Medicine, Weill Cornell Medical College, New York, New York, USA
| | - C. P. Foley
- Citigroup Biomedical Imaging Center, Department of Radiology, Weill Cornell Medical College, New York, New York, USA
| | - S. Vallabhajosula
- Citigroup Biomedical Imaging Center, Department of Radiology, Weill Cornell Medical College, New York, New York, USA
| | - B. Hu
- Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Chicago, Illinois, USA
| | - S. G. DiMagno
- Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Chicago, Illinois, USA
| | - D. Sondhi
- Department of Genetic Medicine, Weill Cornell Medical College, New York, New York, USA
| | - R. G. Crystal
- Department of Genetic Medicine, Weill Cornell Medical College, New York, New York, USA
| | - J. W. Babich
- Citigroup Biomedical Imaging Center, Department of Radiology, Weill Cornell Medical College, New York, New York, USA
| | - D. Ballon
- Citigroup Biomedical Imaging Center, Department of Radiology, Weill Cornell Medical College, New York, New York, USA
- Department of Genetic Medicine, Weill Cornell Medical College, New York, New York, USA
| |
Collapse
|
39
|
Chiang GC, Chang E, Pandya S, Kuceyeski A, Hu J, Isaacson R, Ganzer C, Schulman A, Sobel V, Vallabhajosula S, Ravdin L. Cognitive deficits in non-demented diabetic elderly appear independent of brain amyloidosis. J Neurol Sci 2016; 372:85-91. [PMID: 28017255 DOI: 10.1016/j.jns.2016.11.040] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2016] [Revised: 09/29/2016] [Accepted: 11/16/2016] [Indexed: 12/25/2022]
Abstract
BACKGROUND To determine the effects of Type 2 diabetes (DM2) on levels of brain amyloidosis and cognition in a community-dwelling cohort of nondemented elderly individuals. METHODS 33 subjects (16 DM2, 17 nondiabetic) were prospectively recruited. Subjects underwent a PET scan using the amyloid tracer, Pittsburgh Compound B, and a neuropsychological evaluation. Associations between DM2, brain amyloidosis, and cognition were assessed using multivariate regressions, adjusting for age and APOE4 status. RESULTS DM2 subjects had lower global cognitive function (p=0.018), as measured by the Repeatable Battery for the Assessment of Neuropsychological Status. There was no difference in brain amyloidosis between groups (p=0.25). CONCLUSIONS Community-dwelling, nondemented individuals with DM2 had greater cognitive deficits, which do not appear to be mediated by brain amyloidosis. Further studies exploring potential mediators of these cognitive deficits should be performed.
Collapse
Affiliation(s)
- Gloria C Chiang
- Department of Radiology, Division of Neuroradiology, Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York, NY, United States.
| | - Eileen Chang
- Department of Radiology, Division of Neuroradiology, Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York, NY, United States
| | - Sneha Pandya
- Department of Radiology, Division of Neuroradiology, Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York, NY, United States
| | - Amy Kuceyeski
- Department of Radiology, Division of Neuroradiology, Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York, NY, United States
| | - James Hu
- Department of Radiology, Division of Neuroradiology, Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York, NY, United States
| | - Richard Isaacson
- Department of Neurology, Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York, NY, United States
| | - Christine Ganzer
- Department of Nursing, Hunter-Bellevue School of Nursing, New York, NY, United States
| | - Aaron Schulman
- Department of Medicine, Division of Endocrinology, Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York, NY, United States
| | - Vivian Sobel
- Department of Medicine, Division of Endocrinology, Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York, NY, United States
| | - Shankar Vallabhajosula
- Department of Radiology, Division of Neuroradiology, Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York, NY, United States
| | | | - Lisa Ravdin
- Department of Neurology, Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York, NY, United States
| |
Collapse
|
40
|
Cox B, Vallabhajosula S, Rini J, Ghiuzeli C, Wang L, Kapur A, Potters L, Antony J, Kamvosoulis P, Brown K, Connelly E, Stieb J, Gaballa H, Ben Levi E, Palestro C, Paul D. A Phase I Dose Escalation Study of Targeted Radionuclide Therapy of Malignant Tumors Using 18F Fluorodeoxyglucose (18F-FDG): Initial Experience and Early Results. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1909] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
41
|
Vallabhajosula S, Nikolopoulou A, Jhanwar YS, Kaur G, Tagawa ST, Nanus DM, Bander NH, Goldsmith SJ. Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody. Curr Radiopharm 2016; 9:44-53. [PMID: 25771365 DOI: 10.2174/1874471008666150313114005] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2014] [Accepted: 03/09/2015] [Indexed: 11/22/2022]
Abstract
Prostate specific membrane antigen (PSMA) is the single most well-validated prostate cancer (PCa)-specific cell membrane antigen known. It is present in high levels in 95% of PCa, and is an ideal target to develop radiopharmaceuticals for imaging studies and radionuclide therapy. Humanized J591 monoclonal antibody (mAb) binds specifically with nanomolar affinity to the extracellular domain of PSMA. After binding, the PSMA-antibody complex is rapidly internalized, increasing the potential utility of PSMA as a target for the delivery of mAb-conjugated radionuclides or cytotoxins. J591 mAb was labeled with 177Lu at a high specific activity (10-30 mCi/mg) using DOTA as the bifunctional chelate. The preclinical data in PSMA positive xenografts, strongly suggested that 177;Lu-J591 mAb is an ideal radiopharmaceutical for RIT of metastatic PCa. Since October 2000, five clinical studies (phase I and II) were performed in subjects with metastatic castration-resistant prostate cancer (CRPC) using 177Lu-J591. The methodology and the results of these clinical studies are briefly reviewed in this article. The maximum tolerated dose (MTD) as a single dose was 70 mCi2. Based on dose fractionation (DF), MTD was 90 mCi/m2(2 doses of 45 mCi/m2, 2 wks apart). Phase II study in patients with progressive metastatic CRPC, at a dose of 65- 70 mCi/m2 resulted in significant PSA declines in 60% of the patients. While myelosuppression was the dose limiting toxicity, DF alone or in combination with docetaxel also resulted in significant PSA declines with much less toxicity. 177Lu imaging studies demonstrated accurate targeting of known metastatic sites in >90% of patients and those with stronger PSMA expression by semi-quantitative imaging had more PSA declines. These clinical studies clearly documented the potential therapeutic value of radioimmunotherapy (RIT) in metastatic PCa.
Collapse
Affiliation(s)
- Shankar Vallabhajosula
- Division of Nuclear Medicine and Molecular Imaging, 525 East 68th Street, STARR-221, New York, NY 10065.
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Molina AM, Batra JS, Karir BS, Jhanwar Y, Vallabhajosula S, Christos PJ, Lam L, Epstein J, Karpenko I, Beltran H, Nanus DM, Goldsmith SJ, Bander NH, Tagawa ST. Abstract CT140: Pilot study of “hyperfractionated” anti-prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) for progressive metastatic castration-resistant prostate cancer (mCRPC). Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-ct140] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Phase I and II single dose 177Lu?J591 studies have been published demonstrating safety and efficacy in mCRPC. We reported a study of fractionated-double dose 177Lu?J591 (2 doses given 2 weeks apart), demonstrating the ability to administer higher cumulative doses with a dose-response and also equal or less toxicity. As a single-dose, 70 mCi/m2 results in at least 30% declines in 47% with 41% receiving a platelet transfusion. When administered in 2 divided doses, 80 mCi/m2 results in 25% PSA response with 25% transfusion; 90 mCi/m2 results in 59% response with 65% getting transfused. We hypothesize that additional dose-fractionation will allow a higher cumulative dose with less toxicity.
Methods: Patients with progressive mCRPC with normal neutrophil and platelet counts were enrolled in a planned 6-patient pilot study. No selection for PSMA expression was performed. 177Lu-J591 was administered at 25 mCi/m2 every 2 weeks until the emergence of grade 2 myelosuppression. Planar imaging of 177Lu?J591 at 6?8 days following the 1st and 4th doses was performed. Pre- and post-treatment PSA and CTC counts (CellSearch) were measured.
Results: 6 men median age 68.5 (range 50-79), PSA 84.8 (14.7-2265), 67% elevated LDH, 83% unfavorable CTC count, 67% prior chemo, all prior exposure to abi/enza. Five (83%) with bone mets, 5 (83%) with lymph node mets, and 2 (33%) with visceral mets. Pts received a range of 3-6 doses (cumulative 75-150 mCi/m2 of 177Lu-J591). Two (33%) had >30% PSA decline and 3 (50%) had CTC count decline. Two (33%) experienced Gr 4 neutropenia (without fever), 3 (50%) had Gr 4 thrombocytopenia, and 2 (33%) had platelet transfusion. Two had worsening cytopenia following partial count recovery during periods of cancer progression, with bone marrow biopsies in both revealing infiltrative tumor without dysplasia. Targeting of 177Lu?J591 at known sites of disease was seen in all (100%) pts.
Conclusions: “Hyperfractionation” of radioimmunotherapy with 177Lu?J591 is possible in a heavily pre-treated population with poor prognostic features. Targeted delivery of 177Lu occurs to known sites of disease in an unselected patient population. Study is ongoing to determine the optimal target population and dosing regimen for phase 2 study.
Citation Format: Ana M. Molina, Jaspreet S. Batra, Beerinder S. Karir, Yuliya Jhanwar, Shankar Vallabhajosula, Paul J. Christos, Linda Lam, Jennifer Epstein, Irene Karpenko, Himisha Beltran, David M. Nanus, Stanley J. Goldsmith, Neil H. Bander, Scott T. Tagawa. Pilot study of “hyperfractionated” anti-prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) for progressive metastatic castration-resistant prostate cancer (mCRPC). [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr CT140.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Linda Lam
- Weill Cornell Medical College, New York, NY
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Pinto-Chengot K, Jhanwar Y, Batra J, Karir B, Vallabhajosula S, Christos P, Molina A, Beltran H, Nanus DM, Goldsmith SJ, Bander NH, Tagawa ST. Abstract 3971: Non-invasive assessment of prostate-specific membrane antigen (PSMA) expression as a prognostic marker in men with metastatic castration-resistant prostate cancer (mCRPC). Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-3971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: PSMA is nearly universally expressed by PC, has a correlation with androgen receptor (AR) pathway dysregulation, and some studies have pointed towards PSMA expression as a prognostic marker. Non-invasive measurement of PSMA expression may be biomarker of AR activity in animal models.[Evans et al, PNAS 2011] Anti-PSMA monoclonal antibody J591 has been utilized both for imaging as well as therapeutics and we have published semi-quantitative scoring in the setting of therapeutic clinical trials.
Methods: Patients with mCRPC underwent planar gamma camera imaging following radiolabeled (RL) J591 injection (177Lu- or 111In-J591). RL-J591 images were semi-quantitatively scored using a 5-point visual score (VS) system [Tagawa et al, Clin Cancer Res 2013]. Overall survival (OS) was calculated from the date of imaging to death or last follow up. As several life-prolonging treatments (docetaxel, sipuleucel-T, cabazitaxel, abiraterone (Abi), enzalutamide (Enza), radium-223) became available during the study time period, treatment following RL-J591 imaging was recorded and used in multivariate analysis.
Results: Between 2000 and 2015, 165 patients with mCRPC were imaged following RL-J591 and semi-quantitatively scored for PSMA expression by VS. Baseline demographics included median age of 71.3 years (44.5-85.9); bone metastases present in 86.7%, 52.7% with LN mets, 17% with lung mets, 7.9% with liver mets, 1.8% other mets. Fifty three (32.2%) had low PSMA expression by imaging (VS 0-1) and 112 (67.8%) had high PSMA expression (VS 2-5). Post RL-J591 imaging, 41.2% (68/165) patients received life prolonging therapy, including taxane chemotherapy (33.9%), Abi/Enza (14.5%), sipuleucel-T (1.2%), or radium-223 (1.2%). At last follow up 12.7% (21/165) patients were alive. Median OS was 22.6 months in patients with low PSMA expression and 16.6 mo with high PSMA expression (P = 0.07). Those with subsequent receipt of life prolonging therapy had OS of 23.6 months vs 14.3 mo (P = 0.002). On multivariable analysis controlling for life prolonging therapy, higher PSMA expression by imaging was a significant predictor for poorer OS (adjusted hazard ratio = 1.60; 95% CI = 1.10, 2.31; P = 0.01).
Conclusion: Non-invasive measurement of PSMA expression may be evaluated on a semi-quantitative basis via planar imaging. The level of PSMA expression is inversely associated with survival when controlling for receipt of known life-prolonging therapy. With the introduction of newer quantitative molecular imaging (i.e. PET), quantitative PSMA imaging may prove to be a useful prognostic tool.
Citation Format: Kavya Pinto-Chengot, Yuliya Jhanwar, Jaspreet Batra, Beerinder Karir, Shankar Vallabhajosula, Paul Christos, Ana Molina, Himisha Beltran, David M. Nanus, Stanley J. Goldsmith, Neil H. Bander, Scott T. Tagawa. Non-invasive assessment of prostate-specific membrane antigen (PSMA) expression as a prognostic marker in men with metastatic castration-resistant prostate cancer (mCRPC). [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3971.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Ana Molina
- Weill Cornell Medical College, New York, NY
| | | | | | | | | | | |
Collapse
|
44
|
Tagawa ST, Batra J, Vallabhajosula S, Jhanwar Y, Christos PJ, Emmerich L, Karir BS, Karpenko I, Lam L, Febles VRA, Molina AM, Beltran H, Goldsmith SJ, Bander NH, Nanus DM. Final results of 2-dose fractionation of 177Lu-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.5022] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | - Paul J. Christos
- New York-Presbyterian Hospital/Weill Cornell Medicine, New York, NY
| | | | | | | | - Linda Lam
- Weill Cornell Medical College, New York, NY
| | | | | | | | | | | | | |
Collapse
|
45
|
Amor-Coarasa A, Schoendorf M, Meckel M, Vallabhajosula S, Babich JW. Comprehensive Quality Control of the ITG 68Ge/68Ga Generator and Synthesis of 68Ga-DOTATOC and 68Ga-PSMA-HBED-CC for Clinical Imaging. J Nucl Med 2016; 57:1402-5. [PMID: 27103024 DOI: 10.2967/jnumed.115.171249] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2016] [Accepted: 03/14/2016] [Indexed: 01/03/2023] Open
Abstract
UNLABELLED A good-manufacturing-practices (GMP) (68)Ge/(68)Ga generator that uses modified dodecyl-3,4,5-trihydroxybenzoate hydrophobically bound to a octadecyl silica resin (C-18) as an adsorbent has been developed that allows for dilute HCl (0.05N) to efficiently elute metal-impurity-free (68)Ga(3+) ready for peptide labeling. We characterized the performance of this generator system over a year in conjunction with the production of (68)Ga-labeled DOTATOC and Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (PSMA-HBED-CC) intended for clinical studies and established protocols for batch release. METHODS A 2,040-MBq self-shielded (68)Ge/(68)Ga generator provided metal-free (68)GaCl3 ready for peptide labeling in the fluidic labeling module after elution with 4 mL of 0.05N HCl. The compact system was readily housed in a laminar flow cabinet allowing an ISO class-5 environment. (68)Ga labeling of peptides using GMP kits was performed in 15-20 min, and the total production time was 45-50 min. Batch release quality control specifications were established to meet investigational new drug submission and institutional review board approval standards. RESULTS Over a period of 12 mo, (68)Ga elution yields from the generator averaged 80% (range, 72.0%-95.1%), and (68)Ge breakthrough was less than 0.006%, initially decreasing with time to 0.001% (expressed as percentage of (68)Ge activity present in the generator at the time of elution), a unique characteristic of this generator. The radiochemical purity of both (68)Ga-DOTATOC and (68)Ga-PSMA-HBED-CC determined by high-performance liquid chromatography analysis was greater than 98%, with a minimum specific activity of 12.6 and 42 GBq/μmol, respectively. The radionuclidic ((68)Ge) impurity was 0.00001% or less (under the detection limit). Final sterile, pyrogen-free formulation was provided in physiologic saline with 5%-7% ethanol. CONCLUSION The GMP-certified (68)Ge/(68)Ga generator system was studied for a year. The generator system is contained within the fluidic labeling module, and it is compact, self-shielded, and easy to operate using simple manual techniques. The system provides radiolabeled peptides with high (>98%) radiochemical purity and greater than 80% radiochemical yield. The (68)Ge levels in the final drug products were under the detection limits at all times. (68)Ga-DOTATOC and (68)Ga-PSMA-HBED-CC investigational radiopharmaceuticals are currently being studied clinically under investigational new drug (IND) applications submitted to the U.S. Food and Drug Administration.
Collapse
Affiliation(s)
| | - Megan Schoendorf
- Department of Radiology, Weill Cornell Medicine, New York, New York; and
| | - Marian Meckel
- Isotope Technologies Garching GmbH, Garching, Germany
| | | | - John W Babich
- Department of Radiology, Weill Cornell Medicine, New York, New York; and
| |
Collapse
|
46
|
Batra JS, Karir B, Pinto-Chengot K, Jhanwar YS, Vallabhajosula S, Christos PJ, Hodes G, Lam L, Molina A, Beltran H, Goldsmith SJ, Nanus DM, Bander NH, Tagawa ST. MP50-19 DOSE-FRACTIONATED ANTI-PSMA RADIOIMMUNOTHERAPY (
177
LU-J591) FOR MCRPC. J Urol 2016. [DOI: 10.1016/j.juro.2016.02.453] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
47
|
Batra JS, Karir BS, Pinto-Chengot K, Jhanwar Y, Vallabhajosula S, Christos PJ, Hodes G, Lam L, Molina AM, Beltran H, Nanus DM, Goldsmith SJ, Bander NH, Tagawa ST. Fractionated dose radiolabeled anti−prostate specific membrane antigen (PSMA) radioimmunotherapy ( 177Lu−J591) for progressive metastatic castration−resistant prostate cancer (mCRPC). J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.2_suppl.205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
205 Background: Phase I and II single dose 177Lu−J591 studies have been published. Based on the theoretical advantages of dose fractionation on safety and efficacy, we initiated a phase I dose−escalation study of fractionated−dose 177Lu−J591. Methods: Men with progressive mCRPC with normal neutrophil and platelet counts were enrolled. The initial portion was 3+3 dose−escalation, with 6 cohorts of 3−6 patients receiving 2 doses 177Lu−J591, 2 weeks apart starting with 20 mCi/m2, escalating to 45 mCi/m2. After determining maximum tolerated dose (MTD), patients enrolled in 2 expansion cohorts at recommended phase II doses (RP2D). Planar imaging of 177Lu−J591 at 6−8 days following the initial dose was performed. Pre− and post−treatment PSA was measured for all patients and the highest dose−level cohorts had CTC counts (CellSearch) measured before and after treatment. Results: 48 patients enrolled with median age 74 (55−95) ), median baseline PSA 45.38 (1.93−766.5), 37.5% with prior chemo. The RP2D’s of fractionated 177Lu−J591 were 40 mCi/m2 or 45 mCi/m2 x2 with option for GCSF. Overall PSA decline ≥ 50% in 9 (18.8%), ≥ 30% in 14 (29.2%) and any PSA decline in 26 (54.2%); at RP2D doses (n = 32), 8 (25%) with ≥ 50%, 12 (37.5%) with ≥ 30%, and 20 (62.5%) with any PSA decline. Of 25 with available CTC counts, 14 declined, 8 remained stably favorable, and 3 increased. Of 12 with unfavorable baseline CTC counts, 8 (66.7%) became favorable at follow up, 2 decreased by 30% and 88% but remained ≥ 5, and 2 increased; 1 converted from < 5 to ≥ 5. Thirty-five (72.9%) had grade 3/4 hematological toxicities; 19 (59.4%) with Gr 4 heme toxicity in RP2D cohorts, with 15 (16.9%) receiving at least 1 platelet transfusion, 6 receiving GCSF, and 0 with febrile neutropenia. Overall 4 had Gr 1 transaminitis and 14 (29.2%) had grade 1 infusion reactions (without pre−medication). Accurate targeting of 177Lu−J591 at known sites of disease seen in 84.4%. Conclusions: Fractionated 177Lu−J591 is well tolerated with predictable, reversible myelosuppression, achieving a higher cumulative dose than possible with a single dose. Both PSA and CTC count control was achieved. Clinical trial information: NCT00538668.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Linda Lam
- Weill Cornell Medical College, New York, NY
| | | | | | | | | | | | | |
Collapse
|
48
|
Broft A, Slifstein M, Osborne J, Kothari P, Morim S, Shingleton R, Kenney L, Vallabhajosula S, Attia E, Martinez D, Timothy Walsh B. Striatal dopamine type 2 receptor availability in anorexia nervosa. Psychiatry Res 2015; 233:380-7. [PMID: 26272038 PMCID: PMC5055757 DOI: 10.1016/j.pscychresns.2015.06.013] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2015] [Revised: 04/23/2015] [Accepted: 06/27/2015] [Indexed: 12/31/2022]
Abstract
The neurobiology of anorexia nervosa remains incompletely understood. Here we utilized PET imaging with the radiotracer [(11)C]raclopride to measure striatal dopamine type 2 (D2) receptor availability in patients with anorexia nervosa. 25 women with anorexia nervosa who were receiving treatment in an inpatient program participated, as well as 25 control subjects. Patients were scanned up to two times with the PET tracer [(11)C]raclopride: once while underweight, and once upon weight restoration. Control subjects underwent one PET scan. In the primary analyses, there were no significant differences between underweight patients (n=21) and control subjects (n=25) in striatal D2 receptor binding potential. Analysis of subregions (sensorimotor striatum, associative striatum, limbic striatum) did not reveal differences between groups. In patients completing both scans (n=15), there were no detectable changes in striatal D2 receptor binding potential after weight restoration. In this sample, there were no differences in striatal D2 receptor binding potential between patients with anorexia nervosa and control subjects. Weight restoration was not associated with a change in striatal D2 receptor binding. These findings suggest that disturbances in reward processing in this disorder are not attributable to abnormal D2 receptor characteristics, and that other reward-related neural targets may be of greater relevance.
Collapse
Affiliation(s)
- Allegra Broft
- Columbia University Medical Center/New York State Psychiatric Institute, Department of Psychiatry, 1051 Riverside Drive, New York, NY, USA.
| | - Mark Slifstein
- Columbia University Medical Center/New York State Psychiatric Institute, Department of Psychiatry, 1051 Riverside Drive, New York, NY, USA
| | - Joseph Osborne
- Weill Cornell Medical College, Department of Radiology, New York, NY, USA; Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, NY, USA
| | - Paresh Kothari
- Weill Cornell Medical College, Department of Radiology, New York, NY, USA
| | - Simon Morim
- Weill Cornell Medical College, Department of Radiology, New York, NY, USA
| | - Rebecca Shingleton
- Columbia University Medical Center/New York State Psychiatric Institute, Department of Psychiatry, 1051 Riverside Drive, New York, NY, USA; Boston University, Department of Psychology, Boston, MA, USA
| | - Lindsay Kenney
- Columbia University Medical Center/New York State Psychiatric Institute, Department of Psychiatry, 1051 Riverside Drive, New York, NY, USA
| | | | - Evelyn Attia
- Columbia University Medical Center/New York State Psychiatric Institute, Department of Psychiatry, 1051 Riverside Drive, New York, NY, USA
| | - Diana Martinez
- Columbia University Medical Center/New York State Psychiatric Institute, Department of Psychiatry, 1051 Riverside Drive, New York, NY, USA
| | - B Timothy Walsh
- Columbia University Medical Center/New York State Psychiatric Institute, Department of Psychiatry, 1051 Riverside Drive, New York, NY, USA
| |
Collapse
|
49
|
Glodzik L, Rusinek H, Pirraglia E, Tsui W, Mosconi L, Li Y, McHugh P, Murray J, Williams S, Randall C, Butler T, Deshpande A, Vallabhajosula S, DeLeon M. P4‐253: Effects of metabolic syndrome, antihypertensive medications, and statins on PiB deposition in cognitively normal subjects. Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.08.082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
| | | | | | - Wai Tsui
- New York UniversityNew YorkNYUSA
| | | | - Yi Li
- NYU School of MedicineNew YorkNYUSA
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Berti V, Murray J, Davies M, Spector N, Tsui WH, Li Y, Williams S, Pirraglia E, Vallabhajosula S, McHugh P, Pupi A, de Leon MJ, Mosconi L. Nutrient patterns and brain biomarkers of Alzheimer's disease in cognitively normal individuals. J Nutr Health Aging 2015; 19:413-23. [PMID: 25809805 PMCID: PMC4375781 DOI: 10.1007/s12603-014-0534-0] [Citation(s) in RCA: 104] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
OBJECTIVES Epidemiological evidence linking diet, one of the most important modifiable lifestyle factors, and risk of Alzheimer's disease (AD) is rapidly increasing. However, there is little or no evidence for a direct association between dietary nutrients and brain biomarkers of AD. This study identifies nutrient patterns associated with major brain AD biomarkers in a cohort of clinically and cognitively normal (NL) individuals at risk for AD. DESIGN Cross-sectional study. SETTING Manhattan (broader area). PARTICIPANTS Fifty-two NL individuals (age 54+12 y, 70% women, Clinical Dementia Rating=0, MMSE>27, neuropsychological test performance within norms by age and education) with complete dietary information and cross-sectional, 3D T1-weighted Magnetic Resonance Imaging (MRI; gray matter volumes, GMV, a marker of brain atrophy), 11C-Pittsburgh compound-B (PiB; a marker of fibrillar amyloid-β, Aβ) and 18F-fluorodeoxyglucose (FDG; a marker of glucose metabolism, METglc) Positron Emission Tomography (PET) scans were examined. MEASUREMENTS Dietary intake of 35 nutrients associated with cognitive function and AD was assessed using the Harvard/Willet Food Frequency Questionnaire. Principal component analysis was used to generate nutrient patterns (NP) from the full nutrient panel. Statistical parametric mapping and voxel based morphometry were used to assess the associations of the identified NPs with AD biomarkers. RESULTS None of the participants were diabetics, smokers, or met criteria for obesity. Five NPs were identified: NP1 was characterized by most B-vitamins and several minerals [VitB and Minerals]; NP2 by monounsaturated and polyunsaturated fats, including ω-3 and ω-6 PUFA, and vitamin E [VitE and PUFA]; NP3 by vitamin A, vitamin C, carotenoids and dietary fibers [Anti-oxidants and Fibers]; NP4 by vitamin B12, vitamin D and zinc [VitB12 and D]; NP5 by saturated, trans-saturated fats, cholesterol and sodium [Fats]. Voxel-based analysis showed that NP4 scores [VitB12 and D] were positively associated with METglc and GMV, and negatively associated with PiB retention in AD-vulnerable regions (p<0.001). In addition, both METglc and GMV were positively associated with NP2 scores [VitE and PUFA], and negatively associated with NP5 scores [Fats] (p<0.001), and METglc was positively associated with higher NP3 scores [Anti-oxidants and Fibers] (p<0.001). Adjusting for age, gender, ethnicity, education, caloric intake, BMI, alcohol consumption, family history and Apolipoprotein E (APOE) status did not attenuate these relationships. The identified 'AD-protective' nutrient combination was associated with higher intake of fresh fruit and vegetables, whole grains, fish and low-fat dairies, and lower intake of sweets, fried potatoes, high-fat dairies, processed meat and butter. CONCLUSION Specific dietary NPs are associated with brain biomarkers of AD in NL individuals, suggesting that dietary interventions may play a role in the prevention of AD by modulating AD-risk through its effects on Aβ and associated neuronal impairment.
Collapse
Affiliation(s)
- V Berti
- Lisa Mosconi, Department of Psychiatry, NYU School of Medicine, 145 East 32nd St, 2nd Floor, New York NY, 10016. Tel: (212) 263-3255, Fax: (212) 263-3270
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|